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Summary 
Herpesviruses are clinically and economically important pathogens that establish life-long 
persistence in their animal or human hosts. Despite considerable efforts, up to now vaccines 
which protect against disease are not available, emphasizing the central role of antiviral 
chemotherapy in the control of herpesvirus infections. However, most approved anti-
herpesvirus drugs target solely viral genome replication. These drugs are often associated 
with considerable side effects and cross-resistant strains can occur under therapy. Therefore, 
the comparative study of herpesvirus morphogenesis is important to define new common drug 
targets for herpesviruses. 
 
One of the least understood aspects of viral morphogenesis are the dynamics of viral particle 
transport. Trafficking during infection is studied best by fluorescently labeled virus particles 
in combination with live cell fluorescence microscopy. In recent years, recombinant viruses 
which express fusions of structural proteins to fluorescent proteins (FPs) widely extended our 
understanding of virus morphogenesis. However, studies on beta- and gamma-herpesviruses 
by this method were limited. This was due to the lack of replication competent, capsid-tagged 
fluorescent virus mutants representing these subfamilies. 
 
This thesis reports on the construction and characterization of viable recombinants of Murine 
Cytomegalovirus (MCMV) and Murine Gamma-Herpesvirus 68 (MHV-68) carrying ectopic 
insertions of the small capsid protein (SCP) fused to FPs. 
 
To tag SCPs, their coding sequences were first rated as either conserved or variable domains 
by sequence alignments. Then the fluorescent proteins were inserted into variable linker 
sequences flanking conserved domains. Subsequently, the new fusion constructs were inserted 
ectopically as a second copy into the viral genomes in the presence of the wild type (WT) 
SCP allele and viruses were reconstituted. This way, inhibitory or dominant negative 
properties of the fusion proteins could be assessed. Most resulting recombinant viruses 
replicated with WT kinetics in cell culture. Their bright fluorescence allowed studies on 
particle dynamics by live cell microscopy including single particle tracking during entry and 
egress with high spatial as well as temporal resolution. 
 
In summary, Virus recombinants described here will enable the comparative study of alpha-, 
beta- and gamma-virus capsid dynamics throughout herpesvirus morphogenesis. 
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Zusammenfassung 
Herpesviren sind bedeutende humane Pathogene, die eine lebenslange Persistenz in ihren Wirten 
induzieren. Trotz vieler Versuche ist es bisher nicht gelungen, Impfstoffe zu entwickeln. Aus diesem 
Grund sind anti-herpesvirale Wirkstoffe umso wichtiger. Jedoch haben die meisten zugelassenen 
Wirkstoffe die virale Genom-Replikation als Ziel. Diese Beschränkung auf eine Funktion im 
Replikationszyklus erleichtert das Auftreten von kreuz-resistenten Stämmen bei länger dauernder 
Therapie. Darüber hinaus ruft diese Klasse von Inhibitoren erhebliche Nebenwirkungen hervor. Um 
neue Wirkstoffziele aufzudecken, sind vergleichende Studien über generelle Prinzipien der 
Herpesvirus-Morphogenese wichtig. 
 
Die Prinzipien Viruspartikel-Transportes gehören zu den bisher weniger verstandenen Aspekten der 
Herpesvirus-Morphogenese. Diese dynamischen Prozesse lassen sich am besten mit Hilfe der 
Fluoreszenzmikroskopie in lebenden Zellen verfolgen und analysieren. In den letzten Jahren haben 
rekombinante Viren, die für Fusionen zwischen Strukturproteinen und fluoreszierenden Proteinen 
kodieren, unser Verständnis für die dynamischen Prozesse der Morphogenese stark erweitert. 
Jedoch konnten bisher im Gegensatz zu den alpha-Herpesviren, beta- und gamma-Herpesviren kaum 
mit dieser Methode analysiert werden. Dies ist vor allem dem Fehlen replikations-kompetenter, 
Kapsid-markierter, fluoreszierender Virusmutanten in diesen Sub-Familien zuzuschreiben. 
Diese Arbeit beschreibt die Konstruktion, Charakterisierung und Anwendung von fluoreszenz-
markierten Mutanten des Murinen Cytomegalovirus (MCMV) und des Murinen Gammaherpesvirus 
68 (MHV-68), die ektopische Insertionen des kleinen Kapsidproteins (SCP) fusioniert zu 
verschiedenen Fluoreszenzproteinen (FPs) tragen. 
 
Um lebensfähige SCP-FP-tragende Mutanten zu konstruieren, wurde ein mehrstufiges 
Mutageneseverfahren entwickelt. Zuerst wurden potentiell konservierte Proteindomänen mit Hilfe von 
multiplen Aminosäureabgleichen definiert. Die Gene der FPs wurden dann in potentielle 
Verknüpfungssequenzen zwischen konservierten Domänen eingefügt. Daraufhin wurden die 
Fusionssequenzen ektopisch in die viralen Genome eingefügt. Dies hatte zur Folge, dass 
funktionsbestimmende SCP Sequenzen nicht unterbrochen wurden. Dabei konnten die 
Fusionsproteine auf etwaige hemmende oder dominant-negative Eigenschaften untersucht werden.Die 
resultierenden Virusmutanten wuchsen mit Wildtyp-Kinetik in Zellkultur und helle Fluoreszenzsignale 
konnten sowohl in infizierten Zellen, als auch in aufgereinigten Viruspräparationen nachgewiesen 
werden. Diese rekombinanten Viren eigneten sich dazu, orientierte Partikelbewegungen mit hoher 
zeitlicher Auflösung aufzunehmen und per single particle tracking räumlich zu beschreiben. 
 
Die hier beschriebenen Virusmutanten ermöglichen zum ersten Mal vergleichende Studien zur alpha-, 
beta- und gamma-Herpesvirus Kapsid-Dynamik. 
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1 Introduction 
1.1 Light Microscopy 
1.1.1 Light microscopy and the invention of microbiology 
 
The term microscope comes from the Greek words µικρός, mikrós, "small" and σκοπεῖν, 
skopeîn, "to look" or "see". Therefore, a microscope is literally an apparatus to see small 
things.  
The first (light-) microscopes were built in the 16th century, however it took until the last 
quarter of the 17th century that microscopes were used in biomedical research. A huge impact 
had the work of Antoni van Leeuwenhook. He reported on the discovery of protists in 1674 
and bacteria in 1676 (40). He therefore became the founder of microbiology, the science 
dealing with “unseen life on earth” (undertitile of This week in Microbiology, a podcast by 
Prof. Vincent Racaniello). Since then, microbiology and microscopy are strongly connected. 
 
1.1.2 History of light microscopes 
 
Antoni van Leeuwenhook mostly used very simple microscopes consisting of just one lens 
that were more similar to magnifying glasses. His skill in grinding lenses as well as his good 
eyesight enabled him to build and use some lenses with 200 fold magnification. However, 
compound microscopes that consist of more than one lens were already known at that time 
and, for example, used by Robert Hooke. The disadvantage of this early compound 
microscopes was their strong chromatic aberration, an effect that is caused by the failure of a 
lens to focus all colors to the same convergence point. This problem resulted in a drastic 
decrease in resolution. Therefore, higher magnifying lens combinations could not be used and 
the microscopes, for example used by Robert Hooke, did not magnify more than 20-30 times. 
This physical problem was solved in the 1730s by Chester More Hall with the invention of 
achromatic lenses that employed different types of glass to realign the different wavelengths. 
However, it took until 1827 when Giovanni Battista Amici introduced the first achromatic 
microscope (85).  
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Figure 1-1: Conjugated field planes in a simple compound microscope 
Basic light path in a compound microscope. The sample image (image plane 2) is magnified by the objective 
lens and projected onto image plane 3. The eyepiece then further magnifies this image and projects it onto the 
eye. At the retina, image plane 4 is projected which corresponds to the imaginary image plane 3 at infinity. Total 
magnification is the product of the objective and eyepiece magnification. (Figure adapted from 
http://www.microscopyu.com/articles/optics/components.html) 
 
In contrast to historical compound microscopes, modern light microscopes consist of a 
plethora of lenses to achieve highest image quality. However, their basic principle did not 
change since the invention of compound microscopes more than 400 years ago. 
As shown in Figure 1-1, the basic components are the objective that magnifies the specimen 
and projects the resulting image as an intermediate image.  This is magnified again by the 
eyepiece to produce an image on the cornea of the eye. The magnification of a microscope is 
therefore the product of objective magnification (typically between 4 - 100x) and eyepiece 
magnification (typically 10x). 
 
1.1.3 Optical resolution 
 
The microscopic image of a point source is not a point but a spot called Airy disk due to 
diffraction of light (49). As illustrated in Figure 1-2, two points are just resolved when the 
center of one Airy disk falls on the first minimum of the other Airy disk (Rayleigh´s 
criterion). The radius of the Airy disk therefore defines the lateral resolution of an objective 
(49). It can be calculated as d = (0.61 λ/NA) with λ being the used light wavelength and NA 
the numerical aperture. The numerical aperture (NA) was defined as the maximum cone width 
that can be collected with a given focus (5). This means that with high NA oil objectives  and 
short wavelengths around 450 nm, a theoretical maximum resolution of approximately 200 
nm can be achieved, however, in praxis resolutions range around 250-300 nm.  
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Figure 1-2: Rayleigh criterion for spatial resolution. 
Profile of diffraction patterns (upper panel) and its intensity distributions as a function of separation distance 
(lower panel): (a) the bright Airy disk and 1st- and 2nd-order diffraction rings of a single spot are visible. (b) two 
disks separated by a distance rAiry such that the maximum of a disk overlaps the first minimum of the other 
disk: the points are just barely resolved. (c) two disks at a separation distance of 2 ·rAiry: the points are clearly 
resolved. (Figure and legend adapted from (71) and (49)) 
 
1.1.4 The discovery of fluorescence 
 
Over 150 years ago in 1852, George Gabrial Stokes described a phenomenon which was in 
essence already observed by Nicolás Monardes in 1565 and many others thereafter (106). He 
used a prism to refract sunlight and then held a tube containing a quinine solution into the 
rays. As long as he moved the tube through the visible parts of the spectrum, nothing 
happened. However, when he held it into the invisible part next to the violet portion, the 
solution lit up in blue (106). He later called this phenomenon fluorescence and noted that the 
emitted light was always of a longer wavelength then the exciting light (Stokes shift). 
 
Later the physics of fluorescence was worked out. It is basically the re-emission of light by a 
molecule after absorption of light. A Jablonski diagram as depicted in Figure 1-3 illustrates 
what happens when a photon is absorbed by a fluorophore: The molecule is excited from its 
ground state S0 to a higher electronic state in S1. In picoseconds, the molecule relaxes to the 
lowest vibrational level of S1, which means part of the absorbed energy is released. The 
molecule typically stays in the lowest vibrational level of S1 for nanoseconds. Then, a 
transition to a higher excited level of S0 occurs. During this transition, light is emitted. 
Afterwards, the molecule reaches its thermal equilibrium quickly (3, 6). The Stokes shift can 
therefore be explained by the “loss” of energy before the transition from S1 to S0. Due to this 
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effect, the wavelength of the emitted light is longer and has less energy then the light used for 
excitation (Stokes shift). 
 
 
Figure 1-3: Physics of fluorescence 
Jablonski diagram depicting the energy steps needed to bring a fluorescein isothiocyanate-molecule from one 
energy level to another (upper row). These steps are related to the absorption and emission characteristics (lower 
row). Up-pointing arrows depict the amount of energy (wavelength) a photon has to deliver to excite the 
molecule to a given vibrational state (horizontal lines) in S1 or S2. Down-pointing arrows indicate the amount of 
energy (wavelength) an emitted photon can have. As energy in the form of photons is only emitted from the 
lowest vibrational level of S1, emitted photons have a longer wavelength (less energy) than the absorbed light 
(Stokes shift). (Figure and legend adapted from (57)). 
 
1.1.5 The quest for contrast 
 
Early microscopes used visible light to shine through the sample and illuminate it (brightfield 
microscopy). However, sample contrast was often poor and specific structures, especially at 
higher magnification, were hard to identify. Therefore, different methods were developed to 
increase the contrast. One way is the staining of structures with dyes. A prominent example is 
the Gram stain which was developed by the Danish scientist Hans Christian Gram, who 
published the method in 1884 (45). This method allows the characterization of bacteria into 
two large groups based on the properties of their cell walls. A lot of other stainings were 
developed, many of them still used today. Still, for some applications even higher contrast 
was needed. 
 
1.1.6 The advent of fluorescence microscopy 
 
It took almost another 50 years after the observation of fluorescence by Stokes in 1852, that it 
was realized that fluorescence could be used to increase contrast in microscopy. 1908, Köhler 
and Seidentopf built the first fluorescence microscope (87). The illumination source was a 
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cadmium spark, but it was much too dim to be of practical use. However, two years later 
Lehmann combined suitable filters with a carbon arc. Based on this work, the first 
fluorescence microscopes where sold by Reichert and Carl Zeiss only a year later (87). 
However, suitable fluorescent probes that stained biological samples still had to be developed. 
This was achieved soon after. Especially acridine dyes played an important role after Bommer 
found in 1929 that a certain acridine stained the nuclei of tissue sections (87). 
The breakthrough for fluorescence microscopy followed in 1941 when Albert H. Coons and 
his colleagues reported the specific staining of tissue with a fluorescein labeled antibody 
solution (17, 18, 87). Immunofluorescence was born and its ability to greatly enhance optical 
contrast while being very specific at the same time transformed fluorescence microscopy from 
a technique for specialists into a standard application. 
 
 
Figure 1-4: Molecular structure of wildtype GFP 
Quaternary structure of wildtype GFP depicted as ribbon diagram. Green arrows indicate the typical beta-barrel 
structure consisting out of 11 strands of beta-sheets. Orange, less ordered sequence parts bridge the sheets and 
blue sequence parts fold as alpha-helix. The yellow residues depicted in the middle form the fluorophore. Two 
molecules of wildtype GFP form a dimer in the chrystal structure as well as in solution. (Figure and legend 
adapted from (110)) 
 
1.1.7 The discovery of green fluorescent protein 
 
The invention of immunofluorescence enabled the specific localization of almost any protein 
of interest in fixed cells. However, a simple, widely applicable method to specifically label 
subcellular structures of interest in living cells was still missing. This changed in 1994 when 
Martin Chalfie and his colleagues described the use of a green fluorescent protein (GFP) for 
the genetic labeling of proteins (13). 
 
When this protein was first described by Shimomura et al. (98) in 1962, even the authors 
could not have imagined the impact this protein would eventually have on modern life 
sciences. This jellyfish protein that looked “greenish in sunlight“ and exhibited “a very bright, 
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greenish fluorescence in the ultraviolet of a Mineralite” (98, 105) remained a curiosity for 
almost 30 years until it revolutionized the biological sciences as a genetic fluorescent tag that 
is suitable for live cell imaging (105). From there on, a wide panel of variants was developed 
and other related proteins were found in several invertebrates resulting in a multicolored, 
bright toolbox ready for every life scientist to use (96, 105). 
Subsequently, 46 years after its original description, the Nobel Price in chemistry was 
awarded in 2008 to Martin Chalfie, Osamu Shimomura, and Roger Y. Tsien for their 
discovery and development of the green fluorescent protein (GFP). 
 
1.1.8 Basic structure of modern fluorescence microscopes 
 
Modern fluorescent microscopes can be roughly divided into widefield- and confocal 
microscopes. They both have in common that the same objective is used to excite the sample 
and to collect the emitted light. For this reason, a beam splitter of some sort is needed to split 
the emitted light from the exciting light (Figure 1-5 left). Often so called filter cubes are used. 
These are typically assemblies of 3 filters (Figure 1-5 right). The excitation light is filtered by 
an excitation filter that only permits the desired wavelength(s). The selected light is then 
reflected onto the sample by a dichroic mirror, which transmits most wavelengths but the ones 
used for excitation. The emitted light from the sample is then transmitted through the dichroic 
mirror and subsequently filtered by an emission filter. 
 
 
 
Figure 1-5: Basic beampath in a fluorescence microscope 
The general beampath in an epi-fluorescence microscope is shown (left). The objective is both used to excite the 
specimen and to collect emitted fluorescene. A filter cube is used to separate both beampaths. (right) The 
principle of a filter cube specifically designed for the excitation and detection of GFP (emission and excitation 
characteristics of GFP are overlayed on the dichroic mirror properties in light blue (excitation) and light green 
(emission)) (3). Light from an arc lamp is filtered by an excitation filter (2). Resulting light in the range of 480 
nm is reflected onto the specimen at the dichroic mirror which is non-permissive to this range of wavelenghts. 
Emitted fluorescence light collected by the objective is focused onto the dichroic mirror and permitted through. 
Afterwards, it is filtered by a emission filter (4) to remove last traces of excitation light. (Figure and legend 
adapted from (57)) 
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Figure 1-6: Basic features of widefield and confocal fluorescence microscopes 
The basic constituents and optical pathways of a widefield (left) and a confocal laser scanning microscope are 
shown. In case of a widefield-setup, either an arc lamp or a laser can be used as a light source. In case of a laser, 
the beam is widened to illuminate the whole image and then projected by the objective onto the sample. A 
dichroic mirror separates exciting from emitted light which is further filtered by an additional emission filter. 
The signal is then recorded by a CCD camera. In a confocal setup, a very small diameter laser beam is focused 
onto the sample leading to the illumination of only the confocal volume. The confocal volume is scanned over 
the sample by an xy-scanner consisting of 2 mobile mirrors. The emitted light is focused through an aperture 
called pinhole that eliminates most of the out-of-focus signal. Because the picture is built up over time by 
scanning, the signal from each confocal volume is recorded by a photomultiplier tube or avalanche photo diode. 
(Figure modified from(49)) 
 
The basic features of widefield and confocal laser scanning microscopes (CLSM) are depicted 
in Figure 1-6. In a widefield microscope, the whole image is illuminated and recorded on a 
charge-coupled device (CCD) camera. Typical resolutions range around 300 nm laterally and 
2.5 µm axially. In a CLSM however, only a diffraction limited volume, the so-called confocal 
volume, is illuminated. The dimension of this confocal volume is dependent on the used 
wavelength, the numerical aperture of the used objective and the refractive index of the used 
medium between objective and object (49). Additionally, a confocal pinhole (aperture) is 
placed in front of the detector. This pinhole greatly reduces the detection of out-of-focus light. 
Thereby, an about three times better axial resolution compared to widefield microscopes is 
achieved. Typical resolutions for CLSMs range around 300 nm laterally and around 1 µm 
axially (49). To build up a picture, the confocal volume has to be scanned over the sample. 
This is achieved by using two mirrors, which can be tilted very quickly (Figure 1-6 right). 
Still, scan time can be limiting if high image quality is needed and often widefield setups with 
attached CCD-cameras are superior in speed as well as in sensitivity if state-of-the-art CCD 
cameras are employed.  
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1.1.9 Fluorescence live cell imaging 
 
To enable the fluorescence imaging of living cells, the microscopy setup has to be adapted to 
the environmental needs of the cells in question. Especially if cellular properties are 
quantified, incubation under stable physiological conditions is mandatory to measure 
meaningful data. Most mammalian cells have to be incubated at 37° C in a specific growth 
medium with defined amounts of nutrients, salts and a stable pH. To achieve this, special 
setups were developed over the last decade or so. 
 
 
Figure 1-7: Schematic drawing of a live imaging setup 
An inverted fluorescence microscope is depicted. Most of the body is enclosed in an incubation chamber that is 
heated and controlled by an environmental control unit (right). CO2 is mixed into the air supply to keep the pH 
of the corbonate-buffered cell culture medium constant. A CCD camera to acquire digital images is mounted on 
the left port. (Figure adopted from 
http://www.microscopyu.com/articles/livecellimaging/livecellmaintenance.html) 
 
As shown in Figure 1-7, heating is normally achieved by an enclosure of some sort that is 
used to insulate the sample. Heating is typically done by a combination of devices. Often the 
sample holder is heated. Additionally, the objective can be heated, and the whole enclosure is 
normally supplied with warmed air. To keep the pH of the sample medium stable, either a 
buffered cell culture medium is used, or a carbonate buffer system employed, which needs the 
supplementation of CO2 into the air supply. 
To prevent focus drift during acquisition, the imaging setups are often mounted onto 
vibration-isolated tables as shown in Figure 1-7. Moreover, systems are often set up in 
climatized rooms to prevent focus drifts due to thermal gradients. 
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1.2 Diffusion theory and single particle tracking 
 
1.2.1 Cellular transport processes 
 
Life in the form of a unicellular microbe or a huge multicellular organism heavily depends on 
the flux of substances, or in other words, transport processes. Depending on the distances and 
other factors like the size of the molecule or cargo as well as the viscosity of the surrounding 
medium that need to be bridged, two modes are possible. The first is molecular diffusion, 
which is self-propelled by thermal energy. Larger molecules diffuse by Brownian motion 
which is originated from collisions with solvent molecules. Diffusion can be along 
concentration gradients and these gradients might be maintained by the use of energy, as in 
the case of nuclear-cytoplasmic shuttling of import/export factors (77). The second mode is 
biochemical energy consuming, directed transport of cargo along cellular tracks. 
 
Diffusion is very effective at short distances in dilute environments. As reviewed by Sodeik 
(100), a herpes simplex virus capsid particle of approximately 120 nm in diameter would need 
approximately 14.6 seconds to cross a diameter of 10 µm by diffusion. However, in the 
viscous and crowded intracellular environment, the same particle would need around 2 h. 
Therefore, it becomes clear that big molecules or cargo like a herpesvirus capsid cannot 
depend on diffusion alone to cross the cell. In these cases, the second described mode is 
employed which is the energy-dependent, directed transport along cellular tracks by the use of 
molecular motor proteins. 
 
1.2.2 Methods to study particle mobility in a cellular environment 
 
Several techniques were developed in the last decades to study the mobility of molecules and 
particles in cellular environments. Most of them are based on live cell fluorescence 
microscopy as its high contrast allows the localization of even very small entities. Some 
examples are fluorescence recovery after photobleaching (FRAP), fluorescence correlation 
microscopy (FCS) and single particle tracking (SPT) (as reviewed in (25)). While the two 
former methods mainly provide average information on molecule dynamics, SPT can provide 
information on the mobility of individual molecules or particles (25). 
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1.2.3 Determination of particle positions in SPT 
 
As described before, the optical resolution of light microscopes is diffraction limited. 
Therefore, practically no better resolution than 250 to 300 nm can be achieved with typical 
commercially available systems. This means for example that the architecture of an 
assemblage of fluorescent molecules, such as a virus particle carrying hundreds of individual 
fluorophores, cannot be resolved. However, the position of the center of such a particle can be 
determined to much greater accuracy. The only caveat is that the particle concentration has to 
be sufficiently low to exclude the overlapping of individual particles due to the diffraction 
limit. 
One way to determine the position of a fluorescent particle is to fit its diffraction limited spot 
with a two-dimensional Gaussian function: 
 
                    
 
 
where A0 and σ are the amplitude and the width at half-maximum of the two-dimensional  
Gaussian curve, and x0 and y0 the coordinates of the position of the individual particles (49). 
The positioning accuracy of this method is dependent on the signal to noise ratio but can be as 
high as +/- 2nm (49). Typically it ranges around +/- 10 to 30 nm and is therefore much better 
than the optical resolution as long as particle signals do not overlap. 
 
1.2.4 The mean square displacement as a measure of particle behavior 
 
Once the positional changes of a particle are recorded, the diffusion of a moving particle can 
be described by the behavior of the mean square displacement (MSD) over time. A particle 
diffusing freely describes a random walk. In this case, the MSD is directly proportional to 
time. 
 
<r2(∆t)> = MSD (∆t) = 2kD∆t 
 
where r2(∆t) is the displacement of the particle position within a time interval ∆t, D the 
diffusion coefficient, and k the number of dimensions the particle diffuses in (49). 
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In cases where free particle diffusion is somehow influenced by the surrounding environment, 
different functions can be applied to describe particle movement. 
Three major functions are: 
 
Normal diffusion   MSD = 4 D t 
Anomalous diffusion   MSD = 4 D tα 
Directed motion with diffusion  MSD = 4 D t + (vt) 2 
 
where α is the anomalous exponent and v the velocity of the directed transport (92). 
 
By classifying particle tracks into these classes it is possible to deduce predictions about the 
particle surroundings. For example, a particle exhibiting directed motion is most likely 
associated to a molecular track of some sort like a microtubule. A particle exhibiting 
anomalous diffusion, on the other hand, has to be in some kind of viscous environment which 
inhibits its free diffusion. Thereby SPT can be used to not only describe particle behavior but 
also to probe the direct environment of an individual particle. Especially in virology, SPT can 
be of great use as viruses can be engineered to produce fluorescent virus particles. These 
particles are often smaller than the diffraction limit, but with the above mentioned toolkit it is 
possible to analyze the diffusive behavior of such labeled virus particles at high detail. 
 
1.3 Herpesviruses 
1.3.1 The Order Herpesvirales 
 
Herpesviruses (HVs) are an order of doublestranded DNA viruses (Herpesvirales) which have 
coevolved with their respective hosts for millions of years (86). Currently, 91 different HVs 
are listed by the international committee on taxonomy of viruses (ICTV, 
http://www.ictvonline.org/). The order is divided into three families with the HVs of 
mammals, birds and reptiles in the family Herpesviridae. Fish and frog HVs are clustered into 
the family Alloherpesviridae, and the family Malacoherpesviridae contains the only known 
bivalve HV Ostreid herpesvirus 1. The family Herpesviridae can be further divided into three 
subfamilies named alpha-, beta- and gamma-herpesvirinae (21). This classification was 
originally based on their biological properties, but a profound body of sequence data 
accumulated in the last two decades supports this framework (76). 
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Currently, eight human HVs are known. Three can be grouped into the alpha-subfamily 
(herpes simplex virus 1, HSV-1; herpes simplex virus 2, HSV-2; varicella zoster virus, VZV), 
three into the beta-subfamily (human cytomegalovirus, HCMV; human herpes virus 6, HHV-
6; human herpes virus 7, HHV-7) and two into the gamma-subfamily (Epstein-Barr virus, 
EBV; Karposi-sarcoma associated virus, KSHV).  
 
 
Figure 1-8: Herpesvirus Particle 
The general structure of a herpesvirus particle is depicted with main constituents marked. The left part depicts a 
central cross-section through the virus particle while the right part shows the capsids surface in a particle cross-
section. The linear dsDNA genome (dark blue) is depicted filling up the inner capsid space. Capsid hexons are 
drawn in green, while pentons are depicted in light blue. The number of MCP proteins needed to form hexons 
and pentons is indicated in the right part. The tegument is drawn as an amorphous layer (brown), the inner 
tegument is indicated in darker brown. The envelope is drawn in light blue with different viral glycoproteins 
incorporated (green, brown, yellow). Figure adopted from ViralZone (www.expasy.org/viralzone, Swiss Institute 
of Bioinformatics). 
 
1.3.2 General structure of herpesvirus particles 
 
HV particles consist of a DNA core (ranging from 120 to 230 kb) protected by a highly 
ordered protein shell called capsid. Capsids are ~120 nm in size and share a common T = 16 
icosahedral geometry consisting of 162 subunits. Based on their position on the capsid, these 
capsomers can be subdivided in 150 hexons (the subunits forming the facets) and 12 pentons 
(the subunits at the vertices). Because of their strong conservation, the herpesvirus capsid was 
used historically to classify newly discovered viruses (76). 
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The capsid is surrounded by a more or less amorphous layer of proteins called tegument 
which, according to new data, seems to consist of different assemblies. One function of the 
tegument is the introduction of transcription factors or the subversion of innate host defenses 
right upon entry into the host cell (86). The tegument is surrounded by a host-derived 
membrane called envelope in which a variety of viral membrane proteins are embedded. The 
amount as well as type of embedded glycoproteins varies between herpesviruses. The 
glycoproteins are responsible for recognition of the host cell virus receptors and orchestration 
of the fusion events during virus entry. 
 
1.3.3 The herpesvirus lifecycle 
 
The general HV lifecycle can be divided into a lytic and a latent phase: During the lytic phase, 
a plethora of viral proteins are expressed. Lytic infection of a cell results in the production of 
progeny virus and typically leads to its destruction. 
In certain cell types, HVs can establish latency. Latency is defined as a persistent state during 
which the viral genome is maintained in the host nucleus. Occasionally, viral genomes 
reactivate and a new lytic cycle is started. Typically, only very few viral proteins and some 
non-coding RNAs are expressed during latency, which facilitate genome maintenance and an 
immunological mode of stealth. Reactivation events happen at relatively low rates and are 
normally well controlled by the immune system. However, in immunodeficient hosts the 
reactivated virus can initiate new symptomatic infections. The mechanisms by which latency 
is initiated as well as how reactivation is induced are still not completely understood (86). 
 
1.3.4 Entry of herpesviruses 
 
The process of initial attachment of a herpesvirus particle followed by fusion of the envelope 
with cellular membranes is termed penetration and marks the beginning of a new round of HV 
replication. During this process virus particles initially bind reversibly to glycosaminoglycans 
at the cell surface. In a next step, the envelope fuses with cellular membranes. Fusion occurs 
directly either at the plasma membrane or after internalization of virus particles by 
endocytosis. The actual used pathway depends on the cell type being infected. 
After penetration, the tegument separates and releases the capsid (63). The capsid then 
recruits molecular motors like kinesins and dyneins which enables the microtubule-mediated 
transport to the microtubule organizing center and subsequently to the nucleus (80). Here, 
capsids bind to nuclear pores and inject their genome through the portal into the nucleus (86). 
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Figure 1-9: General herpesvirus lifecycle 
Virus particles attach to the cell surface (1) and either fuse with the plasma membrane (2) or enter by 
endocytosis and subsequent membrane fusion (not shown). After fusion, capsids are recruited onto microtubules 
and transported to the nuclear membrane where they attach to nuclear pores (3-5). The viral DNA is 
subsequently injected into the nucleus and viral transcription and genome replication begins (6). Capsids are 
assembled in the nucleus from preformed subunits (7) and concatameric DNA is packaged into them. During  
this process, the concatamers are cleaved into unit-length genomes (8). Packaged capsids subsequently reach the 
inner nuclear membrane (8) and bud into the perinuclear space (9-10) (primary envelopment). Afterwards, 
primary enveloped particles fuse with the outer nuclear membrane and are released into the cytoplasm. 
Cytoplasmic capsids acquire several layers of tegument and subsequently bud into trans-Golgi-derived 
membranous structures enriched with viral glycoproteins (secondary envelopment). Resulting vesicles are 
transported to the plasma membrane where they fuse and release enveloped virions. (RER: rough endoplasmic 
reticulum; M: mitochondrion; G: Golgi apparatus). (Figure adopted from (67)) 
 
1.3.5 Viral gene expression cascade 
 
After injection into the nucleus, the linear viral genome circularizes and the most important 
decision in the HV lifecycle takes place. In most cases the genomes will remain silent or 
silenced and latency is established. In some rare occasions however, the viral expression starts 
in a highly regulated cascade leading to genome replication and subsequently to the formation 
of new particles. Mechanistically, lytic genes can be grouped into three classes. The first class 
consists of transcription units that do not depend on other viral gene products for their 
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expression. They are called immediate early (IE) genes because they are the first to be 
expressed upon the start of the lytic replication cycle. Still, tegument proteins from the 
incoming particle act as viral transcription factors and can modulate IE gene expression (86). 
The production of IE proteins leads to modulation of the host cell to favor virus replication 
and the expression of early (E) genes are induced. This in turn leads viral DNA replication. 
After viral DNA replication has started, late (L) genes are expressed. Late proteins are mostly 
structural proteins which are needed to form new viral particles (for a review see (86)). 
 
1.3.6 Nuclear steps of morphogenesis 
 
Spatially, the replication machinery is assembled near nuclear domain 10 (ND10) sites. ND10 
sites subsequently break down und prereplicative sites are formed (86). As viral genome 
replication processes, they enlarge with time and coalesce to form replication compartments. 
In this process, host chromatin is marginalized at the nuclear rim (69). 
 
The genome is mainly replicated in a “rolling cycle” mechanism that leads to the formation of 
linear genome concatamers (86). One genome each is packaged into preformed capsids by the 
so-called terminase complex. The ATPase subunit of this complex is conserved in the order 
Herpesvirales but also in T4-like phages of the family Myoviridae (21), which might indicate 
a common ancestry of HVs and tailed DNA bacteriophages (4), and that the nuclear stages of 
HV morphogenesis are perhaps more ancient than the cytoplasmic stages (64, 67). 
 
Capsids are believed to be assembled in replication compartments from preformed capsomer 
complexes which are imported into the nucleus after their assembly from individual 
components in the cytosol. This process is autocatalytic and results in the formation of 
procapsids. Procapsids undergo a structural shift after viral genomes are packaged into them. 
 
After genome packaging, capsids reach the nuclear periphery. The process by which this is 
achieved is not clear yet. An F-actin mediated transport mode was proposed (36) which was 
underlined by the discovery that some alpha-herpesviruses can induce nuclear F-actin (33). It 
is, however, still not clear which molecular motors are employed and which viral proteins are 
involved in these processes. 
 
As nuclear pores seem to be too small to allow the transport of capsids through them at most 
stages of infection, capsids undergo a complex envelopment-deenvelopment at nuclear 
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membranes to reach the cytoplasm (primary envelopment). This process termed nuclear 
egress is dependent on the conserved UL34/UL31 complex in most HVs (86) and either 
occurs directly at the inner membrane or at virus-induced membrane infoldings (12). This 
process seems to involve the phosphorylation and destabilization of the nuclear lamina by 
virus- as well as host-kinases (70). 
 
1.3.7 Cytoplasmic steps of morphogenesis 
 
After capsids reach the cytoplasm, further tegument proteins are acquired. Then, secondary 
envelopment occurs at modified, possibly trans-Golgi-derived cellular membranes (86). This 
results in the formation of vesicles with enveloped virus particles inside. These vesicles, 
possibly mimicking exocytotic cargo, are subsequently recruited onto microtubules and 
actively transported to the plasma. Transport to the plasma membrane again seems to be 
mediated by dyneins and kinesins. There, vesicles fuse and release the virus progeny. This 
last step might also use myosins (84), possibly to cross the actin cortex as reported for cellular 
exocytotic vesicles or to facilitate particle release. 
 
1.3.8 Herpesvirus capsids  
 
The assembly of capsids occurs in the host nucleus as described earlier. At least five 
conserved proteins are needed to assemble basic capsids: The major capsid protein (MCP), 
the triplex monomer (TRI1), the triplex dimer (TRI2), the maturational protease (PR) as well 
as the assembly protein (AP) which is which is released from the C-terminal part of the same 
poly-protein by the autocatalytic PR. Moreover the portal protein (PORT) is needed to 
assemble the portal which is needed for DNA packaging (68). An additional constituent, the 
small capsid protein (SCP) is widely conserved among herpesviruses and forms a complex 
with the MCP in hexons. However it is only essential in beta- and gamma-herpesviruses. 
 
Capsids assemble auto-catalytically on the basis of the scaffold that is most likely determined 
by the AP. Its hexons consist of 6 copies of both MCP and SCP, while pentons are made out 
of 5 copies of MCP only. Together they form a shell with a closely packed inner surface and 
star like outer layer, which were termed floor and external protrusions, respectively (104). At 
trigonal positions, triplexes consisting of one copy of TRI1 and two copies of TRI2 overlay 
the floor (104). Pentons are found at the vertices. One penton-position of each capsid serves 
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as portal, which, at least in HSV-1, consists out of 12 copies of PORT (68). It serves as a site 
for the genome entry into the preformed procapsids during the final packaging step of capsid 
morphogenesis. 
 
As illustrated by cryo-electron microscopy with concurrent image reconstruction, six small 
capsid proteins cover the tips of the crown-like hexon protrusions (68, 104), but not the 
pentons. The SCPs constitute therefore the outermost of the capsid structure. Interestingly, 
these outermost structures appear to be quite similar in beta- and gamma-herpesviruses, but 
have a different appearance in alpha-herpesviruses (104). This observation correlates with the 
fact that the SCP is essential in most beta- and gamma-herpesviruses (8, 78) but dispensable 
in most alpha-herpesviruses (14, 23, 52). 
 
1.4 Murine models of human beta and gamma-herpesviruses 
1.4.1 MCMV as an animal model for HCMV pathogenesis 
 
HCMV is the prototypic beta-herpesvirus. This is mainly due to its importance as a human 
pathogen: As all HVs, HCMV establishes persistence after primary infection in immuno-
competent individuals. It is estimated that the prevalence of CMV infection among adults 
over 40 years ranges from 50% to 80 % in the US (http://www.cdc.gov/cmv/overview.html) 
but might reach near 100% in developing countries. In the western world, it is the major viral 
cause of birth defects, causing deafness and mental retardation (46, 50). 
 
The primary HCMV infection, occurring mainly during the early childhood, is asymptomatic 
or associated with mostly mild pathology but results in establishment of life-long latency. 
Thereafter, persistent HCMV infection in immuno-competent individuals is typically not 
associated with disease. However, HCMV can cause severe disease in immuno-compromised 
individuals like transplant-recipients, AIDS and cancer patients. This includes pneumonitis, 
enteritis, retinitis hepatitis, esophagitis, colitis, encephalitis, polyradiculopathy, adrenalitis, 
and also graft loss (30). 
 
Due to its restricted host range, HCMV infection cannot be studied in animals. This lead to 
the establishment of rodent CMVs as animal models, especially murine CMV (MCMV) for 
HCMV pathogenesis. These in vivo models were very fruitful in elucidating the basic 
mechanisms by which CMVs hijack the immune system. 
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Since the establishment of reverse genetics for MCMV (66), this model virus is also used to 
study beta-herpesvirus morphogenesis in cell culture. Cloning of the infectious MCMV 
genome as the first HV bacterial artificial chromosome (BAC) became a milestone in HV 
genetics in general. It provided the basic genetic tools to study essential genes, which was 
very cumbersome using traditional methodology (8, 9). Moreover, compared to HCMV, 
MCMV has several technical advantages too. Its replication cycle is much shorter (1 day 
compared to 3-5 days), the kinetics of its lytic infection is far more synchronous, it is 
permissive in widely accessible and well-characterized mouse cell lines (instead of hard to 
standardize human primary lines) and its security classification as safety level 1 (S1) 
organism allows its study in standard molecular biology labs. In addition, MCMV strains 
show outstanding genetic stability compared to HCMV isolates, which suffer major genome 
rearrangements due to their adaptation into tissue culture (28). Still, the basic characteristics 
of beta-herpesvirus biology are conserved between HCMV and MCMV (e.g. very similar 
dependence on the same set of essential genes). This makes MCMV an ideal tool to study 
principles of beta-herpesvirus morphogenesis in vitro. 
 
1.4.2 Murine gamma-herpesvirus 68 as model for EBV and KSHV pathogenesis 
 
The gamma-herpesviruses currently include two known human herpesviruses. EBV is an 
oncogenic virus. After primary infection, which is mostly asymptomatic in childhood while 
often associated with the clinical syndrome of infectious mononucleosis during or after 
adolescence, the virus establishes persistence in B-lymphocytes. This state of the virus is 
associated with a variety of oncogenic diseases like Burkitt´s lymphoma in subsaharan africa, 
Nasopharynx Carcinoma or Posttransplant Associated Lymphoid Disease (PTLD). 
 
The Human Herpesvirus 8 or Karposi´s Sarcoma associated Herpesvirus (KSHV) was 
discovered as a cause of the Karposi´s Sarcoma, a vascular tumor, which is mainly found in 
HIV infected individuals. KS meanwhile became one of the most frequent forms of cancer in 
Africa. Other KSHV-associated diseases are the Multicentric Castleman´s Diesease as well as 
the Primary Effusion Lymphoma. 
 
 
 
Analogous to HCMV, the human gamma-herpesviruses EBV and KSHV are highly species-
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specific. Therefore, as in the case of HCMV, the discovery of a small rodent model virus had 
a major impact on the understanding of the in vivo biology of gamma-herpesviruses (73). 
 
The MHV-68 isolate of Murid herpesvirus 4 was originally isolated from bank voles (Myodes 
glareolus) in Slovakia (6), but closely related viruses were also found in shrews and wood 
mice (39). In stark contrast to EBV and KSHV which are often hard to culture due to their 
strong propensity to latently infect most cell types, MHV-68 is strongly lytic in cell culture 
and grows to high titers. In comparison to EBV, it also does not immortalize B-cells in cell 
culture. However, it is a robust model of gamma-herpesvirus latency and reactivation in vivo. 
Two closely related MHV-68 lab strains were cloned as bacterial artificial chromosomes 
(BACs) (2, 109) and reverse genetics systems are available for this virus. It is therefore a 
convenient model to study the otherwise hardly accessible basic mechanisms of lytic gamma-
herpesvirus biology in cell culture. 
 
1.4.3 Fluorescent herpesvirus particles uncover the dynamics of herpesvirus 
morphogenesis 
 
Besides the the many open questions of HV morphogenesis, the most elusive ones are the 
principles of viral particle transport. These dynamic events are studied best by fluorescently 
labeled virus particles in combination with live cell fluorescence microscopy. In recent years, 
recombinant viruses expressing fusions of structural proteins to fluorescent proteins widely 
extended our understanding of the dynamic processes involved in the morphogenesis of a 
large number of different viruses (19, 24, 32, 34, 41, 44, 55, 59, 83, 91, 108). 
 
The reported labeling approaches concerning herpesviruses can be roughly divided into three 
groups. The first approach is the labeling of a glycoprotein. This allows the tracking of the 
first steps of infection from attachment to fusion with host membranes, or after envelopment 
to release (42, 79). The second approach is the utilization of a tegument protein as fusion 
partner (29, 31, 91). Depending on the protein used, this approach allows the tracing of events 
after fusion until the separation of the tagged tegument component from the capsids and 
before envelopment after the attachment of the fusion product to the capsid. The last approach 
utilizes a capsid protein such as SCP and pUL25 (14-16, 24, 99). Only this approach allows 
the tracing of all steps of viral entry until the release of viral genomes and morphogenesis 
after capsid assembly. However, a combination of these approaches (3, 22, 72, 103) can be 
useful to discern morphogenesis steps, e.g. enveloped from non-enveloped capsids. A capsid-
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tagged recombinant virus is therefore most desirable as it allows the tracing of almost all 
morphogenesis steps. Until now, however, only alpha-herpesviruses like HSV-1, 
pseudorabies virus (PRV) and equine herpes virus type 1 (EHV-1) (15, 16, 24, 38, 99) could 
be engineered to express fluorescent capsids. In contrast, all attempts to fuse fluorescent 
proteins to beta- or gamma-herpesviruses capsid proteins failed so far (8, 48, 88). 
 
1.5 Aims of this thesis 
 
Despite the different principles of pathogenesis of the eight human herpesviruses, most 
pioneering basic research was so far done on alpha-herpesviruses. It is, however, not clear to 
what extend results obtained in one subfamily fit the situation in other herpesviruses. This is 
especially important considering that most currently approved HV reactive drugs target viral 
genome replication which is conserved among HVs. However these drugs also affect the host 
DNA metabolism and have considerable side-effects. In addition cross-resistant strains can 
appear. Thus comparative studies on the herpesvirus lytic life cycle are needed to discover 
new virus specific drug targets. Therefore, there is an urgent need for targeted comparative 
studies of key functions of HV morphogenesis. These are only possible since the introduction 
of reverse genetics into all subfamilies (2, 7, 66, 72). 
 
As described above, the dynamics of viral capsid transport during herpesvirus morphogenesis 
by live cell imaging were studied mostly in the alpha-herpesvirus models using capsid tagged 
recombinants. This was due to the lack of fluorescent, capsid-tagged beta- and gamma-
herpesviruses. 
We therefore aimed to establish new recombinant beta- and gamma-herpesviruses expressing 
labeled capsids by fusing a fluorescent protein (FP) to a capsid protein. Unfortunately, the 
SCPs of beta- as well as gamma-herpesviruses are essential. All reported attempts to fuse a 
fluorescent protein to SCPs of these subfamilies resulted in non-viable or even dominant 
negative mutants  
 
Herpesvirus capsid proteins undergo numerous and highly ordered interactions with 
themselves or other proteins to build the capsid (48). The pure bulk of several copies of 
fluorescent proteins (FPs) that are needed to deliver a bright fluorescent signal induce sterical 
problems and might render the recombinant viruses non-viable. As first described by Desai et 
al. (24), the SCP of some alpha-herpesviruses like HSV-1, PRV (99) VZV (14) and EHV (38) 
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seem to tolerate an aminoterminal fusion to FPs. This capsid protein is exceptionally suitable 
as a fusion partner as it is located at the outermost of the core-capsid structure, which 
apparently gives sufficient steric freedom to accept a fusion to bulky fluorescent proteins. 
Moreover, it is a very abundant protein with 900 copies per capsid (6 copies per hexon), 
which results in a sufficiently bright fluorescent signal if fused to a fluorescent protein. Yet, 
later studies showed that the aminoterminal fusion with GFP nonetheless renders the product 
biologically non-functional in PRV (52). It emerges therefore, that the tagging of alpha-
herpesvirus-SCPs is apparently only possible because they are not essential for virus 
replication. 
 
This thesis reports on the successful construction of fluorescent capsid-tagged MCMV as well 
as MHV-68 recombinants. Successful construction of FP labeled viruses involved a multi-
step-approach: First, potentially conserved protein domains were defined by multiple 
sequence alignments on the amino acid level. Then, fluorescent proteins were inserted into 
potential linker sequences between conserved domains. Subsequently, the resulting fusion 
proteins were inserted ectopically into the viral genome leaving the respective WT SCP locus 
untouched. This way any inhibitory or dominant negative feature of the fusion proteins could 
be easily assessed. The resulting recombinant viruses were viable and exhibited bright 
fluorescence signals. 
They were then used to study capsid transport both during virus entry and egress by single 
particle tracking. It could be shown that fluorescently labeled virus particles were transported 
actively along extracellular protrusions prior entry, and that intracellular transport of particles 
is mostly directed and dependent of microtubules. 
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2 Materials and Methods 
2.1 Cells and viruses 
 
BALB/c murine embryonic fibroblasts (MEFs), M2-10B4 bone marrow stromal cells (ATCC 
CRL-1972), and NIH-3T3 fibroblasts (ATCC CRL-1658) were prepared and treated as 
described previously (65). Rat embryonic fibroblasts stably transfected to express Cre-
recombinase (REF-Cre) as well as baby hamster kidney cells (BHK, ATCC CCL-10) were 
cultured as described in (2). 
 
All MCMV recombinants used in this work are based on the pSM3fr-∆m1-16-FRT BAC (62). 
The corresponding virus MCMV-∆m1-16-FRT lacks 16 genes from the left end of the 
genome that are not required for virus replication in tissue culture. The morphogenesis of 
MCMV-∆m1-16-FRT was analyzed extensively in previous studies and found to be 
indistinguishable from the wildtype (WT) BAC derived MCMV. Therefore, MCMV-∆m1-16-
FRT is designated as WT throughout this work (62). All recombinant viruses were 
reconstituted from their respective BACs by nucleofection of NIH/3T3 cells. Nucleofection 
was done using an Amaxa 96-Well Shuttle system (Lonza) according to the manufacturer’s 
instructions for NIH-3T3 cells. In brief, 5x105 cells were nucleofected with 400 ng purified 
BAC-DNA and seeded together with 1.5x105 non-transfected cells into one well of a 24 well 
plate. Three days after nucleofection, the cell layer was checked for plaques and split 1:4. 
Usually, six days after nucleofection, full cytopathic effect (CPE) could be observed. Cultures 
were harvested and samples were frozen as passage zero. Afterwards, virus inoculi were 
scaled up on M2-10B4 cells as described previously (65).  
 
All MHV-68 mutants used in this work are based on the pHA3 BAC (2). To generate an 
acceptor BAC for ectopic insertions of transgenes, the M1 gene was deleted by ET-mediated 
homologous recombination (Vidy et al. manuscript in preparation) and called it pHA3-D2. 
The M1 gene deletion has been shown to have no influence on virus replication, neither in 
tissue culture nor in vivo, except for a stronger tendency to reactivate from latency. The 
construction of pHA3-D2 is briefly described in chapter 1.4. Reconstitution of all MHV-68 
BACs was done by lipofecting REF-Cre cells (2) in 6-well plates with BAC DNA mediated 
by Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. 
The infectivity of MCMV as well as MHV-68 preparations was quantified on MEFs by 
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standard plaque assay (81). 
 
To biologically clone MHV-68 mutants, limiting dilutions of reconstituted viruses were done 
by infecting REF-Cre cells in 96-well plates with 0.1, 1 and 10 particle forming units (PFU) 
per well. After 4 days, wells were checked for single fluorescent plaques. The supernatant of 
these wells was saved and cells fixed and checked for revertant, non-fluorescent plaques by 
staining against MHV-68 proteins with a polyclonal serum (101). Supernatant from single 
wells with single fluorescent plaques, lacking any sign of non-fluorescent infectivity, was 
used to inoculate virus stocks. 
 
2.2 Analysis of viral growth in vitro 
 
MEFs were infected with the viruses to be analyzed in duplicate at a multiplicity of infection 
(MOI) of 0.1 for MCMV or 0.01 for MHV-68 at 37o C. The inoculi were removed after 1 h, 
then the cultures were washed three times with Dulbecco´s phosphate-buffered saline 
(DPBS), normal medium was added and the incubation was continued. Supernatants of 
infected cells were harvested daily on days 1 to 6 for MCMV or days 1 to 4 for MHV-68 after 
infection, and the amounts of the released infectious particles were determined by plaque 
assay (81) on MEFs. 
 
2.3 Measurement of plaque sizes 
 
To determine mean plaques sizes, standard plaque assays were performed (81). Four (MHV-
68) or five (MCMV) days after infection, the overlay was removed and cells were fixed with 
4% paraformaldehyde (PFA) for 10 min. Afterwards standard immuno-staining was 
performed against IE-1 (MCMV) or SCP (MHV-68) with specific mouse monoclonal 
antibody solutions and Alexa-coupled mouse specific secondary antibodies (Invitrogen). 
Digital images of individual plaques were obtained using LSM 510 or LSM 710 confocal 
laser scanning microscopes (Zeiss). Plaque diameters in pixels were measured on the digital 
images using ImageJ software (1) and converted into micrometers. 
 
2.4 Plasmid construction 
 
To generate the plasmid pOTO-S-GFP-SCP we amplified a sequence with primers SCPPfor 
and SCPPrev (Table 1) binding to positions 74153-74173 and 73766-73786 of the MCMV 
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Smith strain (NCBI Reference Sequence: NC_004065.1), respectively. The amplicon coded 
for a proposed m48.2 promoter sequence as well as the first 34 amino acids (aa) of m48.2. 
The primer SCPPfor added an EcoRV site to the 5´ end, while SCPPrev fused AflII and SpeI 
sites as well as a hemagglutinin (HA)-tag coding sequence to the 3´ end. The PCR fragment 
was cut with EcoRV and AflII and inserted into the previously described plasmid pO6-IET-
gfpSCP (82) replacing its AflII -SspI fragment. 
 
Further variants of pOTO-S-GFP-SCP coding for SCP fusions to mCitrine and mCherry 
where generated by amplifying the respective fluorescent proteins with primers SP-AflII-FP-
BsrGI and ASP-AflII-FP-BsrGI (Table 1) from YFP-Rac2 (Joel A. Swanson/Addgene) or 
pmCherry-C1 (Clontech) which added AflII and BsrGI sites to the respective ends. The PCR-
products were cut with BsrGI and AflII and and inserted into the plasmid pOTO-S-GFP-SCP, 
replacing its BsrGI-AflII fragment resulting in pOTO-S-mCitrine-SCP and pOTO-S-mCherry-
SCP, respectively. pOTO-S-GFP-SCP and above described variants are coined rescue vectors 
through this thesis as they are used to generate recombinant viruses by a single step ectopic 
rescue (10). 
 
To generate the S-GFP-SCP* mutant, lacking the last 14 C-terminal codons of the SCP open 
reading frame (ORF), the parental vector pOTO-S-GFP-SCP was cut with PvuII and ApaI 
thereby removing the coding sequence for the last 17 aa of the C-terminal region of m48.2. To 
subsequently restore the missing nine codons as well as the stop codon, the corresponding 
region pOTO-S-GFP-SCP was amplified with primers SP-MCP and ASP-MCP (Table 1) and 
inserted by PvuII and ApaI resulting in pOTO-S-GFP-SCP*. 
 
To generate pOTO-ORF65-EGFP we amplified a sequence corresponding to position 102895-
103759 in the MHV-68 BAC genome (2) with primers ORF65for and ORF65rev (Table 1). 
The amplicon coded for a proposed ORF65 promoter sequence as well as the whole ORF65. 
The primers added an SspI and BclI site to the amplicon. The PCR fragment was then cut with 
SspI and BclI and inserted into the above described plasmid pOTO-gfpSCP (88) which 
resulted in pOTO-ORF65. 
 
pOTO-ORF65-GFP was generated by amplifying the GFP coding sequence fom pEGFP-C1 
(Clontech) with primers EGFP65for and EGFP65rev (Table 1) which added StuI and ApaI 
sites to its ends and inserting this fragment into pOTO-ORF65. 
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pOTO-ORF65-mCherry was generated by digesting pOTO-ORF65-EGFP with StuI and ApaI 
and inserting a PCR product generated by using primers mCherry65for and mCherry65rev 
(Table 1) using pmCherry-C1 (Clontech) as template which was digested with AfeI and ApaI. 
(20) pOTO-ORF65-EGFP and above described variants are coined rescue vectors through this 
thesis as they are used to generate recombinant MHV-68 by a single step ectopic rescue (see 
chapter 1.4). 
 
Recombinational cloning to generate yeast bait and prey vectors for yeast two hybrid (Y2H) 
tests was essentially done as described in Fossum et al. (37). The plasmids pOTO-S-GFP-SCP 
or pOTO-S-GFP-SCP* were used as PCR templates for insert amplification with primers 
attB1-S-GFP-SCP-attB2-SP, attB1-S-GFP-SCP-binding-negative-No-Stop-attB2-ASP and 
attB1-SCP-S-GFP-SCP-no-stop-attB2-ASP (supp. Table 1). Resulting PCR products were 
subjected to BP-recombination by Gateway-mediated recombination into pDONR-221 
according to the manufacturer’s instructions (Invitrogen). Subsequently, the coding regions 
were transferred to the prey plasmid pGADCg (102), generating the plasmids pGADCg-S-
GFP-SCP and pGADCg-S-GFP-SCP* which code for a C-terminal fusion to the activation 
domain (AD). 
 
The integrity of all constructs mentioned above was confirmed by restriction pattern analysis 
and DNA sequencing of modified elements. 
 
2.5 Construction of recombinant MCMV and MHV-68 BACs 
 
To generate an acceptor vector for the ectopic insertion of MHV-68 SCP-fusions, we replaced 
the M1 gene with an FRT site. To this end, a PCR product was generated with the primers Del 
M1 for and Del M1 rev (Table 1) on the pcp15 plasmid as a template. This linear fragment 
was then used to delete the region from bp 10662 to bp 12579 of the MHV-68 pHA BAC (2) 
representing M1 gene by homologous recombination mediated by recombinases expressed 
from the plasmid pKD46 The inserted Kanamycin-resistance cassette was subsequently 
deleted by an Flp-mediated recombination as described earlier (10). The resulting BAC was 
called pHA3-D2. 
To insert the expression cassettes encoded by the above described rescue plasmids into the 
MCMV or MHV-68 BACs, we used the single step FRT/Flp system described originally for 
2 Materials and Methods 
 
 26
MCMV (10). Escherichia coli strain DH10B (Invitrogen) containing the MCMV pSM3fr-
∆m1-16-FRT BAC (62) or the MHV-68 pHA3-D2 BAC and the temperature-sensitive Flp 
recombinase expression plasmid pCP20 (85) were transformed with the various R6K gamma 
driven pOTO-constructs (88) carrying the different SCP fusions and treated as described 
previously (82). Correct recombination was verified by analysis of the restriction patters of 
the respective BACs and sequencing of the inserted ORF. 
 
2.6 Yeast two hybrid analysis 
 
Y2H analysis of interactions between SCP constructs and MCP was performed as described 
in the manufacturer’s protocol (BD Biosciences/Clontech). Briefly, the bait plasmid 
pGBKT7-MCP (37) was transformed into the yeast strain Y187 while the prey plasmids 
pGADCg-S-GFP-SCP and pGADCg-S-GFP-SCP* were transformed into the AH109 strain. 
Diploid yeast cells carrying both vectors were generated by mating the strains and subsequent 
selection on SDC-Leu-Trp medium. Growth of diploid cells on SDC-Leu-Trp-His medium 
was used to assess bait-pray interaction via the HIS3 reporter. Bait and prey vectors without 
inserts were used as a control. 
 
2.7 Density gradient purification of virus particles 
 
Nycodenz-gradient purification was essentially done as described in Doehner et al. (27). In 
brief, supernatants from virus-infected cells were centrifuged at low speed (5500 g/15 min) to 
remove cell debris. Afterwards, virus particles were concentrated by high-speed 
centrifugation (23000 g/210 min) and the resulting virus pellet was carefully resuspended in 
VS-buffer (0.05 M Tris, 0.012 M KCL, 0.005 M EDTA, pH 7.8). Free DNA/RNA was 
removed by overnight treatment with 625 U/ml Benzonase (Novagen) at 4° C. Afterwards, the 
resulting suspension was loaded onto a continuous 10-40 % Nycodenz (Axis-Shield) density 
gradient prepared on a GradientStation ip (Biocomp) and separated at 20000 g for 105 min in 
a Beckman SW28 rotor at 4° C. The resulting bands were visualized and collected on a 
GradientStation ip. Each fraction was analyzed by standard negative-stain electron 
microscopy (EM) (47), verifying their integrity and purity. 
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2.8 Analytical polymerase chain reactions (PCRs) 
 
Viral DNA was extracted from cell culture supernantant of infected cells and gradient purified 
virions using the DNeasy blood and tissue kit (Qiagen) according to the manufacturer’s 
instructions. For qualitative analysis, PCR amplification was done using High-Fidelity PCR 
system (Roche) according to the manufacturer’s instructions. PCR products encoding 
potential SCP fusions were gel-purified and sequenced. 
 
In the case of MCMV, the viral DNA from purified virions was quantified by real-time PCR 
using an ABI Prism 7700 sequence detector (Applied Biosystems). Prior to amplification, the 
DNA which was extracted from gradient-purified, Benzonase (Novagen) treated virions and  
digested with PaeI for 1h, 37 °C followed by heat inactivation. To determine the ratio of viral 
DNA copy number to PFU, a quantitative PCR was performed for each sample in triplicate 
using MCMV M54 specific primers and probes as described by Scrivano et al. (95). Viral 
DNA copy numbers were calculated by relating the determined crossing point to a standard 
curve. The standard curve was generated by using serially diluted pSM3fr-BAC DNA as 
templates with known copy numbers and determining their crossing points based on the 
inherent M54 sequence. To normalize for loss of DNA during purification, we determined the 
ratio of a defined quantity of pSM3fr-BAC DNA before and after purification. 
In the case of MHV-68, the viral DNA was purified and quantified by real-time PCR as 
described in (35). 
 
2.9 Immunoblotting 
 
In the case of MCMV, viral protein expression was analyzed 48 h after infection of a 
confluent layer of M2-10B4 cells in 6 cm dishes at a MOI of 1. Subsequently, cells were 
washed with DPBS and lysed in total lysis buffer (62.5 mM Tris, pH 6.8, 2% (v/v) sodium 
dodecyl sulfate (SDS), 10% (v/v) glycerol, 6 M urea, 5% (v/v) β-mercaptoethanol, 0.01% 
(w/v) bromophenol blue, 0.01% (w/vol) phenol red) plus 125 U of Benzonase (Novagen) for 
90 min at 4° C. After denaturation at 95° C for 10 min, samples were loaded onto 15% SDS-
polyacrylamide gels and separated by electrophoresis (SDS-PAGE).  
 
To analyze proteins from purified virions, a sample corresponding to approximately 1.1x105 
PFU of gradient-purified virus preparation per lane was mixed with trichloracid to a final 
concentration of 13% and incubated over night at 4° C. Precipitated protein was pelleted by 
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centrifugation at 15.000 g for 15 min. The supernatant was discarded, the pellet was air-dried, 
and resuspended in total lysis buffer, neutralized with 1M NaOH, loaded onto a 15% SDS-
polyacrylamide gels and separated by SDS-PAGE. 
After SDS-PAGE, separated proteins of MCMV were transferred onto Hybond-P membranes 
(Amersham Biosciences) in the presence of blotting buffer (25 mM Tris, 192 mM glycine, 
20% (v/v)] methanol, pH 8.3). Membranes were blocked in TBS-T (Tris- buffered saline, 
0.05% (v/v) Tween 20) containing 5% BSA for 1 h at room temperature (RT). To detect the 
SCP of MCMV, a polyclonal antiserum directed against SCP was generated by immunizing 
rabbits with Ovalbumin (OVA) -coupled peptides corresponding to aa 36-50 and 59-86 m48.2 
ORF (Metabion). To detect MCP, a rat polyclonal antiserum was used (88). GFP was detected 
by a polyclonal rabbit antiserum (Invitrogen). The blocked membranes were incubated with 
the respective antisera overnight at 4° C and subsequently washed with TBS-T and incubated 
with the appropriate horseradish peroxidase-conjugated (POX) secondary antibody (Dianova). 
The HA-tag was detected with a HA-specific, POX-conjugated monoclonal rat antibody 
(Roche) according to the manufacturer’s instructions. 
 
In the case of MHV-68, one million NIH-3T3 cells were infected at a MOI of 1 in 6-well 
plates and incubated for 24 h. Subsequently, cells were washed with DPBS and lysed in total 
lysis buffer, and blotted as described in (82). To detect MHV-68 SCP, a hybridoma 
supernatant was used (43). A polyclonal anti-MHV-68 rabbit serum was used as to detect 
further virus proteins as a loading control (101). GFP was detected by a polyclonal rabbit 
antiserum (Invitrogen) and mCherry by a polyclonal rabbit antiserum (kindly provided by T. 
Mertens, Ulm). The membranes were incubated with the appropriate horseradish peroxidase-
conjugated secondary antibody (Dianova). 
 
All Western blot reactions were visualized with SuperSignal West Dura Extended Duration 
Sustrate (Pierce) using a Fusion luminiscence reader (Vilber). 
 
2.10 Immobilization of virions on glass coverslips 
 
Immobilization of MCMV virus particles was performed by loading approximately 1x105 
PFU of density gradient-purified virus preparations diluted in 200 µl DBPS onto fibronectin-
coated glass coverslips and incubated for 1 h at 37°C. In the case of MHV-68, supernatant 
from infected cells was cleared by low-speed centrifugation (1200 g/ 5 min) and loaded 
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directly onto fibronectin-coated glass coverslips and further processed as described above. 
After binding, virions were subjected to immunostaining as described below. 
 
2.11 Immunostaining for microscopy 
 
Indirect immunofluorescence (IF) analysis was carried out on glass slides, channel- or 8 well 
µ-slides (Ibidi) by fixing cells or virions with 4 % PFA in DPBS (w/v) for 10 min at 37° C. 
The fixative solution was replenished twice with DPBS and the cells were permeabilized for 
10 minutes with a solution of 0.1% Triton X-100 in DPBS. After extensive washing with 
DPBS, the cells were blocked using 3 % (w/v) bovine serum albumin (BSA) in DPBS 
(blocking solution) for 1 h at RT. Primary antibodies (see chapter 1. 8 for detailed 
description) were applied in blocking solution and incubated with the cells or virions at room 
temperature (RT) for 1 h followed by three DPBS washing steps and 1 h incubation at RT 
with 1:1000 dilutions of Alexa Fluor-conjugated, specific secondary antibodies (Invitrogen) 
in blocking solution. After a final extensive washing step with DPBS, the preparations were 
imaged directly or mounted on glass slides with Prolong Gold resin (Invitrogen). 
 
2.12 Fluorescence microscopy 
 
Confocal laser scanning microscopy was performed with either a Zeiss LSM510 Meta system, 
a LSM710 system or an Olympus FV1000 system equipped with high numerical aperture oil 
immersion objectives. GFP and mCitrine proteins were excited with a 488 nm laser line. 
mCherry was excited with a 543 nm or 561 nm laser line. Protein fluorescence emission was 
detected using corresponding filter sets of the microscopes. Alexa Fluor-Dyes were detected 
corresponding to the manufacturers’ instructions. Pinhole diameters were adjusted to a width 
corresponding to an optical slice thickness of 1 µm for all channels. Pixel sizes were chosen 
based on the Nyquist criteria and varied around 110 nm/Pixel in case of a 63x, NA 1.4 
objective. In general, imaging conditions were chosen which resulted in an optimal 
compromise between light exposure and detector noise and were kept constant in between 
acquisitions of the same experiment.  
 
Live cell imaging was performed with cells growing in µ-slides (Ibidi) or glass-bottom dishes 
(MatTek). During acquisition, the cells were incubated in an environmentally controlled 
chamber at 37°C with either 5% CO2 or in CO2-independent medium (Invitrogen). All images 
were processed according to the guidelines of the Journal of Virology 
2 Materials and Methods 
 
 30
(http://jvi.asm.org/cgi/reprint/85/1/1) using ImageJ (1) as well as Photoshop CS4 (Adobe) 
software. Specially, noise in time-lapse stacks was reduced by Kalman filtering in ImageJ. 
Gradial bleaching was corrected by using the ImageJ Bleach Correction plugin (written by J. 
Riedorf). All images were contrast-enhanced to optimize for printing. 
 
2.13 Single Particle Tracking 
 
The single virus particle fluorescence patterns obtained were fitted by a two-dimensional 
Gaussian function:  
 
                    
(Equation 1) 
 
where A0 and σ are the amplitude and the width at half-maximum of the two-dimensional  
Gaussian curve, and x0 and y0 the coordinates of the position of the individual virus particles. 
The single particle tracking procedure was automated using a custom-written Labview 
software (National Instruments) (51). 
 
For each trajectory, a set of values for the square displacement, r²(t), between two 
observations separated by the time lag tlag = n · ∆t (where ∆t is the time interval between 
successive frames of the movies, n = 0, 1, 2, …, N-1 with N being the total number of points 
in a trajectory) was computed according to: 
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The Mean Square Displacements MSD= >< )²(tr  were then plotted for every time lag tlag and 
the MSD plots were fitted for the 10% first time lags (10 points) assuming three different 
modes of possible motion (92): 
 
Normal diffusion   MSD = 4 D t    (Equation 3) 
Anomalous diffusion   MSD = 4 D tα    (Equation 4) 
Directed motion with diffusion MSD = 4 D t + (vt) 2   (Equation 5) 
 
where D is the diffusion coefficient, α the anomalous exponent and v the velocity of the 
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directed transport. 
 
To determine for each single trajectory which mode of motion described the data best, each 
MSD plot was fitted by Equations 3, 4 and 5 and the reduced chi-squared of the fits were 
compared. The normal diffusion model (Equation 3) was used as long as the more complex 
model functions of for anomalous diffusion (Equation 4) and directed motion with diffusion 
(Equation 5) did not resulted in a at least two-fold decrease of the reduced chi-squared of the 
fit. In cases in which this condition was fulfilled, the mode of motion with the minimum 
reduced chi-squared was chosen. Hence, this procedure leads to the clustering of diffusing 
particles into three distinct classes representing different modes of diffusion. 
 
Track separation of entry data was done manually by choosing sub-trajectories in which the 
particles clearly exhibit long-distance movements. Each obtained sub-trajectory was then 
analyzed individually by computing their MSDs and fitting the resulting MSDs plots 
according to Equation 5. 
 
2.14 Transmission electron microscopy 
 
NIH 3T3 or M2-10B4 cells were grown on carbon-coated sapphire discs and infected at a 
MOI of 0.5 with centrifugal enhancement at 1600 g/RT for 30 min. After an additional hour, 
the inoculum was replaced by normal medium and cells were incubated for 48 h. Then, cells 
were fixed by high-pressure freezing with an HPF 01 instrument (M. Wohlwend GmbH), 
freeze-substituted, and plastic embedded as described previously (107). Embedded samples 
were thin-sectioned and viewed on a Zeiss EM 10 at 80 kV in transmission mode. The 
phenotype of infected NIH 3T3 or M2-10B4 cells did not differ. Pictures were recorded on 
EM film (MACO), digitalized at 1200 dots per inch, contrast-enhanced and sharpened with an 
unsharp mask according to the guidelines of the Journal of Virology 
(http://jvi.asm.org/cgi/reprint/85/1/1) in Photoshop CS4 (Adobe). 
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3 Results 
 
3.1 Construction of capsid-tagged fluorescent beta- and gamma-herpesviruses 
 
Our aim was to study beta- and gamma-herpesvirus capsid dynamics in living cells. While 
viable capsid-tagged alpha-herpesviruses were reported some time ago (14, 24, 38, 99) no 
viable, fluorescent, capsid tagged beta- or gamma-herpesviruses could be achieved. 
Therefore, we first dissected the published approaches to succeed in generating capsid-tagged 
fluorescent herpesviruses. Most previous attempts have in common that they tried to label the 
SCP. Due to the location of this protein at the outer shell of the capsid, it should allow bulky 
protein-tags to be added without sterically disturbing important protein-protein interactions. 
However, the SCP is essential in beta- and gamma-herpesviruses (8, 48, 78), but not essential 
in HSV, PRV and VZV (14, 23, 52). 
Therefore, we set out to develop mutagenesis approaches that would allow us to fuse a 
fluorescent protein to the essential SCP, while at the same time keep the recombinant viruses 
viable. 
 
3.1.1 Construction of capsid-tagged MCMV recombinant 
 
All published trials to tag beta-herpesvirus capsids were based on the direct fusion of the FP 
at the very N-terminus of the SCPs, which resembled the strategy originally published by 
Desai et al. (24). The resulting fusion proteins were non-functional and in some cases even 
dominant-negative, thereby preventing virus reconstitution (8, 48, 88). 
Therefore, we reasoned that a free N-terminus or a sequence motif at the very N-terminus of 
the beta-herpesvirus SCP is essential for its function. This was further supported by an 
alignment of aa sequences of all annotated beta-herpesvirus SCPs, which showed some 
conservation in this region (Figure 3-1). 
Of most importance in this context was the observation that MCMV encodes for a GS-linker 
like sequence in its SCP N-terminus (aa 10 to 34). This linker seems to separate the N-
terminus into two distinct regions (Figure 3-1). We proposed that this linker gives the N-
terminus the flexibility that may be required for its interaction with other capsid proteins. A 
bulky fusion partner like GFP would either hinder these interactions by sterical means, or the 
given flexibility of this linker sequence may not tolerate the unusual enlargement in size. 
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Figure 3-1: Alignment of beta-herpesvirus SCPs sequences 
The shown alignment of all annotated beta-herpesvirus aa sequences was done with T-Coffee 
(http://www.igs.cnrs-mrs.fr/Tcoffee/tcoffee_cgi/index.cgi). Colors indicate the alignment quality ranging from 
blue (“bad”) to red (“good”). A naturally occurring glycin-serin-linker like sequence separates the N-terminus in 
MCMV. The very N-terminal region until the black arrow was dublicated and fused to various tags followed by 
the full length SCP. 
 
Therefore, we decided to duplicate the very N-terminal region consisting of the first 34 aa and 
fused it, separated by an additional linker and a HA-tag, to the N-terminus of GFP. This 
construct was then fused to the full length SCP sequence, which includes a second, WT-copy 
of the N-terminal domain (Figure 3 2). As this construct is composed of the first third of SCP 
(S), the GFP and the full length SCP, we named this construct S-GFP-SCP. To allow BAC 
technology-based insertion into the viral genome by an Flp mediated reaction, we constructed 
these fusion genes using the previously published pO6-IET-gfpSCP plasmid (88). The 
plasmid pOTO-S-GFP-SCP was inserted ectopically into the pSM3fr-∆m1-16-FRT BAC. As 
the coding sequence of the fluorescent protein (FP) in the pOTO-S-GFP-SCP vector was 
flanked by SpeI-sites, it allowed the SpeI-mediated removal of the FP resulting in a fusion 
construct that was just tagged with an HA-tag. This construct was used to control for size 
dependent effects of the insertion. To enable the detection of the construct also in different 
imaging setups, we replaced the GFP coding sequence with the open reading frames of 
mCitrine or mCherry, keeping the same SCP context. Figure 3-2 generally depicts the resulting 
constructs. 
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Figure 3-2: Construction of MCMV S-FP-SCP fusion proteins. 
Detailed representation of the S-GFP-SCP fusion protein as well as the basic genetic layout of the used mutant 
viruses carrying a fluorescent protein (FP) and a hemagglutinin tag (HA). GFP or mCherry were used as FPs. 
The FP could be removed by a simple SpeI-mediated digest resulting in a construct encoding for just a HA-
tagged SCP (S-HA-SCP). N marks the duplicated N-terminal region of SCP. The plasmids carrying the fusion 
constructs were inserted into the MCMV BAC by Flp-mediated recombination. 
 
3.1.2 Reconstitution and basic characterization of recombinant MCMVs 
 
Transfection of the pSM3fr-∆m1-16-FRT-pOTO-S-FP-SCP constructs in NIH-3T3 cells 
resulted in fluorescent plaques with a distinct fluorescence pattern, which mainly localized to 
the nuclei of infected cells (see Figure 3-1 for a representative example of the S-GFP-SCP 
expressing recombinant). Plaque morphologies as well as size were comparable to WT virus 
plaques (Figure 3-3 and Figure 3-4 B). Comparable results were obtained for the other S-FP-
SCP and the S-HA-SCP expressing recombinants (Figure 3-4 B). To elucidate the growth 
kinetics of the recombinant virus, we performed multi-step growth curves on MEF cells. The 
S-GFP-SCP as well as the S-HA-SCP mutant showed WT-like growth kinetics (Figure 3-4 
A). 
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To compare the infectivity of the S-GFP-SCP virions to that of WT virions, we determined 
the genome to PFU ratio. To this end, we prepared gradient purified virus stocks of both 
viruses that were routinely checked for virion integrity and purity by negative-stain electron-
microscopy. Subsequently, we determined the infectivity of the preparations by standard 
plaque assay as well as genome copies by quantitative PCR. The measured genome copies 
should equal the amount of DNA packaged into virus particles, as the virus stocks were 
treated with the DNA-degrading enzyme Benzonase during the purification process.  
 
 
Figure 3-3: Plaque-phenotype of tagged MCMV mutants. 
WT (WT) as well as mutant viruses coding for either HA- (S-HA-SCP) or HA-GFP-tagged SCP (S-GFP-SCP) 
were titrated on MEF cells. 4 days post infection (dpi) cells were fixed with PFA and processed for 
immunofluorescence against the HA-epitope. The scale bars represent 100 µm. 
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Figure 3-4: Tagged MCMV mutants are viable. 
(A) Multistep growth curve of mutant viruses in comparison to WT virus. (B) Comparison of plaque diameters 
of simultaneously titrated WT, HA-, GFP-, and mCherry-tagged virus 4 days post infection (dpi) on MEF cells. 
(C) Genome to PFU ratio of GFP-tagged and WT virus. The ratio between genome content and titer for two 
independently prepared and purified virus stocks per virus was determined by titration and quantitative PCR in 
triplicates.  
 
Average values from two independent gradient purifications with concurrent quantification of 
genome copies in triplicate, as well as titration to determine the amount of PFU, suggested 
that the S-GFP-SCP recombinant virus produces a genome to PFU ratio similar to that of WT 
virus (23 vs. 25 genomes/PFU, respectively) (Figure 3-4 C). From these data we concluded 
that our new SCP labeling approach did not detectably affect viability and infectivity of the 
recombinant MCMV. 
 
3.1.3 Construction of fluorescent, capsid-tagged MHV-68 recombinants 
 
As we were successful in the construction of a viable, capsid-tagged MCMV, we next asked if 
we could transfer this capsid-labeling strategy to gamma-herpesviruses. Because both the 
previously reported HSV-1 recombinant (22, 24, 72) and the MCMV-S-FP-SCP can 
productively infect MEF cells, we decided to modify MHV-68, which is the only known 
gamma-herpesvirus that infects mouse cells productively in vitro. We reasoned that by 
generating a capsid-tagged MHV-68, we would have a panel of labeled model viruses in 
hands that represented all three herpes subfamilies. With such a system, one cell type could 
serve to compare general principles of herpesvirus morphogenesis. 
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Figure 3-5 Alignment of gamma-herpesvirus SCP sequences with ClustalW (REF). 
A naturally occurring glycin-serin-linker like sequence separates the N-terminus and C-terminus of the 
Alcelaphine herpesvirus 1 (AlHV1) SCP and also in the Ovine herpesvirus 1 (OvHV1) SCP sequences. MHV-68 
SCP is referred as MuHV4. 
 
Sequence alignments greatly facilitated the determination of potential insertion sites in the 
case of beta-herpesviruses, therefore we applied the same strategy to gamma-herpesvirus 
SCPs. Figure 3-5 shows a ClustalW alignment of all gamma-SCP sequences currently 
available in Uniprot (www.uniprot.org). Corresponding to this alignment, the N-terminal 
region until approximately position 140 to 150 as well as the very C-terminus seemed to be 
conserved. Surprisingly and similarly to MCMV SCP, a glycine-serine rich sequence stretch 
could be found in the Alcelaphine herpesvirus 1 (AlHV1) SCP and to a limited extent also in 
the Ovine herpesvirus 1 (OvHV1) SCP sequence as well as just before the less conserved C-
terminal domain n the other sequences, indicating a hinge region between the two conserved 
parts of the gamma-HV SCPs, can be found. This stretch apparently separated the longer 
conserved N-terminal region from the shorter C-terminal region, indicating structural domains 
interspaced by a flexible linker sequence. We therefore reasoned that the insertion of an FP 
between these two potential protein domains should be tolerated in the MHV-68 ORF65, as it 
was the case in MCMV. 
3 Results 
 
 38
 
 
Figure 3-6: Construction of MHV-68 ORF65-FP fusion proteins. 
Detailed representation of the ORF65-FP fusion protein as well as the basic genetic layout of the used mutant 
viruses carrying a fluorescent protein (FP)). GFP or mCherry were used as FPs. N marks the N-terminal and C 
the C-terminal region of SCP. The plasmids carrying the fusion constructs were inserted into the MHV-68 BAC 
by Flp-mediated recombination. 
 
We therefore cloned the ORF65 coding sequence as well as the 300 bp upstream sequence as 
a probable promoter sequence into the R6K gamma driven pOTO-backbone generated for the 
MCMV tagging (Figure 3-6). The EGFP or mCherry coding sequence was inserted directly 
into the MHV-68 SCP between aa 132 and 133 without further addition of linker sequences. 
The resulting plasmids pOTO-ORF65-GFP and pOTO-ORF65-mCherry were then transferred 
by Flp-mediated recombination into a modified MHV-68 BAC (pHA3-D2) harboring an FRT 
site replacing the M1 gene, resulting in a recombinant virus coding for both a WT- and a 
second tagged SCP copy. 
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Figure 3-7: Plaque phenotype of GFP-tagged MHV-68 mutant. 
WT (WT) as well as mutant viruses coding for either HA- (S-HA-SCP) or HA-GFP-tagged SCP (S-GFP-SCP) 
were titrated on MEF cells. 4 days post infection (dpi) cells were fixed with PFA and processed for 
immunofluorescence against the HA-epitope. The scale bars represent 50 µm. 
 
3.1.4 Reconstitution and basic characterization of recombinant MHV-68s 
 
Similar to the reconstitution of capsid-tagged MCMV recombinants, transfection of REF-Cre 
cells with recombinant MHV-68 BACs resulted in fluorescent plaques with a distinct 
fluorescence pattern, which mainly localized to the nuclei of infected cells (Figure 3-7). 
Plaque-morphology as well as -size were again comparable to WT plaques (Figure 3-7 and 
Figure 3-8 B). The same results were obtained for the ORF65-mCherry expressing 
recombinants (Figure 3-8 B). To elucidate the growth kinetics of the recombinant virus, we 
first studied the influence of the M1 deletion and FRT-site insertion. We therefore performed 
multi-step growth curves on MEF cells. The ORF65-GFP encoding recombinant was 
comparable to WT-virus. Interestingly, the MHV-68-D2 parental mutant grew slightly better 
compared to WT-BAC derived virus (Figure 3-8 A). 
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Figure 3-8: Tagged MHV-68 mutants are viable. 
(A) Multistep growth curve of MHV-68-D2 (D2) and MHV-68-D2-ORF65-GFP (65-GFP) in comparison to WT 
virus (WT). (B) Comparison of plaque diameters of simultaneously titrated WT, GFP and mCherry-tagged (65-
mCherry) virus 4 dpi on MEF cells. (C) Genome to PFU ratio of GFP- and mCherry-tagged virus in comparison 
to WT virus. The ratio between genome content and titer for two independently prepared and purified virus 
stocks per virus was determined by titration and quantitative PCR in triplicates.  
 
The infectivity of the ORF65-GFP tagged virions was compared to that of the WT by 
determining the particle to PFU ratio. We observed in pretests that supernatants of MHV-68 
infected cells seemed to contain only small amounts of cell debris compared to MCMV. 
Therefore, it sufficed to use precleared (1200 g/ 5 min) supernatants of MHV-68 infected 
cells, which were harvested before cytopathic effect occurred. As described for MCMV, we 
determined the infectivity of the preparations by standard plaque assay as well as the genome 
content by quantitative PCR in triplicates. Average values of particle to PFU ratios suggested 
that the ORF65-EGFP virus produced very similar infectivity compared to WT virus (Figure 
3-8 B C). Altogether, we concluded that our new tagging approach was associated with only 
minor effects on viability and infectivity of the recombinant MHV-68. 
 
3.2 Characterization of Labeled Particles 
 
Having shown that the MCMV S-FP-SCP as well as the MHV-68 ORF65-FP mutants had 
growth properties comparable to their respective WT-parents, we wanted to analyze if these 
viruses produced fluorescent virus particles and not only fluorescent proteins. To this end, 
MCMV or MHV-68 virions were immobilized on fibronectin-coated cover-slips and IF 
analysis was performed. An antiserum against the MCP (88) was used for MCMV, while a 
monoclonal antibody directed against MHV-68 SCP was used for MHV-68 to stain virus 
capsids. Additionally, an antiserum directed against the SCP fusion partner GFP was used in 
both cases to amplify possible weak endogenous GFP signals (Figure 3-9).  
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Figure 3-9: S-GFP-SCP produces a high percentage of labeled virus particles. 
Gradient purified virus particles were immobilized on fibronectin-coated cover-slips, fixed and processed for 
immunofluorescence. A MCP specific polyclonal serum was used as indicator of virus capsids and a GFP 
specific polyclonal antiserum was used to compare MCP and GFP specific signals. Direct GFP fluorescence was 
detected by excitation with 488 nm laser light and appropriate emission filters. Inserts depict 2x magnifications. 
Scale bars represent 10 µm and 2.5 µm in inserts. 
 
We then recorded the corresponding fluorescence signals and counted particle numbers in 
representative areas with the ImageJ plugin “Analyze Particles”. Colocalization was 
determined with the “Colocalization” command and subsequent counting of colocalized 
particles. In the case of MCMV we counted altogether 2653 MCP-positive particles. 91.46% 
+/- 3.88% of them colocalized with an antiserum directed against GFP, indicating that a high 
amount of particles incorporated detectable amounts of S-GFP-SCP. 83.42 % +/- 3.64% of all 
MCP-positive particles could also be detected by their endogenous GFP fluorescence. 
 
In the case of MHV-68, 4807 particles out of 4972 (96.88 %) positive for SCP colocalized 
with the anti-GFP stain, while 4500 particles or 90.57 % detected by their GFP fluorescence 
colocalized with the SCP stain (Figure 3-10), indicating a slightly higher percentage of 
particles that could be visualized by their GFP labeling compared to MCMV S-GFP-SCP. 
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Figure 3-10: ORF-65-GFP labeled MHV-68 produces a high percentage of GFP labeled virus particles. 
MHV-68 virus particles were immobilized on fibronectin-coated cover-slips, fixed and processed for 
immunofluorescence. An SCP specific polyclonal serum was used as indicator of virus capsids and a GFP 
specific polyclonal antiserum was used to compare SCP and GFP specific signals. Direct GFP fluorescence was 
detected by excitation with 488 nm laser light and appropriate emission filters. Inserts depict 2x magnifications. 
Scale bars represent 10 µm and 2 µm in inserts. 
 
Knowing the approximate proportion of GFP labeled particles produced by the respective 
viruses, we next wanted to determine the approximate ratio between GFP-labeled and non-
labeled SCP molecules on virus capsids. Thus, we used WT and GFP virus preparations and 
visualized the mean ratio of tagged to WT SCP by Western blotting and concurrent immuno-
staining specific to SCP and GFP. Gradient-purified virus stocks were used in the case of 
MCMV as well as MHV-68 to reduce contamination by free proteins originating from cell 
lysis to a minimum. We used two antisera per virus, one reacting with GFP and the other with 
either MCMV or MHV-68 SCP. 
 
In the case of MCMV, we could detect WT SCP in the parental as well as GFP tagged virus at 
approximately 15 kD, which is a little more than its calculated size of about 10 kD (Figure 
3-11). By using the GFP reactive serum, we found several S-GFP-SCP specific bands. The 
upper two bands running at approximately 50 kD could also be detected by an antiserum 
reactive to SCP, indicating that at least these two bands correspond to S-GFP-SCP 
derivatives. These data indicated that the fusion protein is incorporated into virus particles. 
However, the detected specific bands were again running higher than the calculated molecular 
weight of the S-GFP-SCP, which is 42 kD. This might be in general due to the low 
complexity region at the N-terminus of the MCMV SCP, which contains a high amount of 
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glycins and serins. 
 
 
 
Figure 3-11: GFP-labeled SCP is incoporated into MCMV S-GFP-SCP virus particles. 
Immunoblot of gradient-purified virus particles. Approximately 1.1*105 particles per lane were TCA-precipitated 
and lysed in total lysis buffer. Proteins were separated by SDS-PAGE, blotted and immunodetected with 
polyconal sera for MCMV, SCP and GFP. 
 
On the MHV-68 virion WB, we could detect the WT SCP protein at its calculated molecular 
weight of approximately 22 kD. The SCP-GFP fusion could be also detected at its calculated 
size of 49 kD. In comparison to MCMV S-GFP-SCP, no additional bands could be found 
(Figure 3-12).  
 
To establish the approximate ratio between labeled and non-labeled SCP for both viruses, we 
quantified the SCP reactive signals and compared them with the signal found for WT SCP in 
the same lane by ImageJ. 
For MCMV, the upper two S-GFP-SCP bands were used for quantification. An approximate 
signal ratio of GFP-fused SCP to unlabeled SCP of one third to two thirds was found. 
According to the current model of CMV virions, 900 WT SCP are incorporated into CMV 
particles (111). Therefore, our findings would translate to an average of 600 copies WT SCP 
and about 300 copies of S-GFP-SCP molecules per virus particle. 
For MHV-68 we found a ratio of approximately two fifth of labeled to three fifth of non-
labeled SCP. This would translate into about 540 copies of WT SCP and 360 SCP-GFP 
copies per virus particle (Figure 3-12). 
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Figure 3-12: GFP-labeled SCP is incorporated into MHV-68 virus particles 
MHV-68-D2 (D2) or MHV-68-D2-ORF65-EGFP (65-GFp) virus particles were gradient purified from 
supernatants and pelleted. Pellets were subsequently lysed in total lysis buffer. Proteins were separated by SDS-
PAGE, blotted and immunodetected with a monoclonal antibody directed against MHV-68 SCP (anti SCP) or a 
polyclonal serum against GFP (anti-GFP). An antiserum against actin was used to control for cytoplasmic 
impurities. 
 
3.3 MCMV S-GFP-SCP interacts with MCP 
 
We could show that purified virus particles are fluorescent and that this fluorescence 
colocalizes with an anti-MCP staining. However, this assay is not sufficient to distinguish 
between a specific incorporation of the S-GFP-SCP into the capsid and the unspecific 
incorporation of the fusion protein into virions via the tegument due to its high abundance late 
in infection (see Figure 3-17). Therefore, we asked whether the S-GFP-SCP fusion protein 
could specifically engage with the capsid or a capsid constituent. It has been shown that 
HCMV SCP and MCP interact via a short C-terminal peptide of the SCP (54). We therefore 
checked first whether this was also true for the MCMV homologues used in our study. To this 
end, we deleted the corresponding peptide in the S-GFP-SCP fusion protein and tested this 
mutant (S-GFP-SCP*) as well as the parental S-GFP-SCP in an Y2H setup against MCP. The 
S-GFP-SCP fusion protein interacted with MCP while the S-GFP-SCP* mutant lacking the 
proposed MCP-binding region did not. 
 
Knowing that S-GFP-SCP interacts with MCMV MCP via its MCP-binding motif, we were 
able to control the interaction between the S-GFP-SCP and the MCP in the virus context. It is 
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reported that the nuclear concentration of the HCMV SCP is dependent on its binding to MCP 
in the cytoplasm because it lacks a functional nuclear localization signal (NLS) (54). The 
observation of strong nuclear GFP signals in S-GFP-SCP infected cells (Figure 3-13) might 
therefore already argue for a MCP-dependent localization of S-GFP-SCP fusion proteins. To 
test this hypothesis directly, we constructed a recombinant MCMV expressing the S-GFP-
SCP* mutant protein lacking its MCP interaction peptide. Cells infected with this 
recombinant virus did not show a specific nuclear S-GFP-SCP* accumulation, but instead a 
homogenous distribution of GFP fluorescence throughout the whole cell (Figure 3-13). We 
concluded that the S-GFP-SCP mutant interacts with MCP specifically and is therefore most 
likely correctly incorporated into the viral capsid during viral morphogenesis. 
 
 
Figure 3-13: S-GFP-SCP nuclear transport is MCP dependent. 
MEFs were infected at very low MOI with viruses expressing ectopically either S-GFP-SCP (top) or a S-GFP-
SCP fusion protein lacking its proposed MCP-interaction peptide (S-GFP-SCP*, bottom). Cells were overlaid 
with methyl-cellulose after infection and fixed and processed for immunofluorescence 4 dpi. GFP fluorescence 
was visualized directly while the cytoplasm and cell nuclei were counterstained with a high concentration of TO-
PRO-3, thereby staining whole cells but still indicating the cell nuclei. The mutant lacking the MCP interacting 
peptide is localized throughout the cyto- and nucleoplasm. Scale bars indicate 10 µm. 
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3.4 Assessment of the genetic stability of capsid-tagged recombinant viruses 
 
Viral genomes carrying unfavorable mutations are facing negative evolutionary pressure. The 
occurrence of adaptive genetic changes in a mutant locus is consequently a sign of reduced 
fitness associated with a mutation. This is important as beta- and gammaherpesvirus SCPs are 
essential for virus replication and thus even small growth defects combined with the strong 
recombinogetic potential of herpesviruses might lead to accumulation of non-fluorescent 
revertants. We therefore assessed the genetic stability of the capsid-tagged MCMV and 
MHV-68 mutants 
 
3.4.1 MCMV S-GFP-SCP and S-HA-SCP labeled virus mutants are genetically stable 
 
To address the genetic stability and to assess the fitness of our constructs, we passaged the S-
GFP-SCP carrying virus 10 times on M2-10B4 cells. The number of 10 passages was chosen, 
as this is the maximum amount of passages used in our laboratory procedures. As controls we 
used WT virus and S-HA-SCP tagged virus. We reasoned that the latter serves as a good 
control for insertion-size dependent effects, given the very small size of the HA-tag compared 
to GFP. 
 
First, we wanted to know how our fusion product was expressed and which changes in protein 
expression occurred after extended passages. We therefore infected M2-10B4 cells with 
passages 0, 5, and 10 of the above mentioned viruses. 48 hours post infection (hpi) cells were 
lysed and immunoblots specific for GFP, SCP and HA were performed. As shown in Figure 
3-14, we could detect a SCP specific signal in all MCMV infected samples, however, the 
corresponding band (g in Figure 3-14) migrated again higher as predicted. Corresponding to 
this finding, we detected an S-HA-SCP specific band (band f) at approximately 22 kD instead 
of its predicted 12 kD with both the SCP and the HA tag specific antisera. In lanes 
corresponding to S-GFP-SCP infected cells, we could define three bands (bands a,b,c) that 
stained specific for SCP, GFP and the HA-tag. The two smaller ones (bands b and c), running 
near the 46 kD marker band were reminiscent of the ones found in purified virions (Figure 
3-11) while a slower migrating band running beneath 58 kD (band a) marker was not detected 
in virions. Moreover, we could detect two more bands (bands d and e) beneath 46 kD which 
were stained positive only by the anti-GFP antiserum and seemed to be also found in blotted 
virus particles (Figure 3-11). More important, no major changes in protein expression levels 
nor in the banding pattern of SCP isoforms could be detected throughout 10 passages of any 
3 Results 
 
 47
of the recombinant viruses tested. These data indicated that the expression of the SCP fusion 
proteins by the recombinant viruses was stable for extended periods. 
To test the genetic stability of the ectopic SCP locus at the sequence level, we amplified the 
region including the insertion locus by PCR from DNA purified from supernatants of cells 
infected with either passage 0, 5 or 10 of S-HA-SCP or S-GFP-SCP expressing viruses. The 
resulting PCR products were gel-purified, sequenced and checked for sequence alterations. 
Again, no alteration could be detected in either of the samples, arguing for extended genetic 
stability of both the S-HA-SCP and the S-GFP-SCP loci. 
 
 
Figure 3-14: Viruses carrying labeled SCP mutants are genetically stable. 
Immunoblot of M2-10B4 cells infected with either WT, S-HA-SCP, or S-GFP-SCP virus derived from passages 
0, 5 or 10 after reconstitution. Cells were infected at a MOI of 1, and harvested 48 hpi by lysis in total lysis 
buffer. Proteins were separated by SDS-PAGE, blotted and immunoprobed for GFP, SCP, HA and MCP as well 
as beta-tubulin as loading controls. Lower case letters indicate specific protein bands. 
 
3.4.2 MHV-68-D2-ORF65-FP viruses express less SCP-FP isoforms 
 
As more SCP- and GFP-reactive bands could be detected on Western blots from MCMV-S-
GFP-SCP infected cells, we next wanted to know if this was also the case for the ORF65-GFP 
tagged MHV-68 mutant. Here we had also the opportunity to compare SCPs tagged with 
different FPs after different number of passages. We therefore infected NIH-3T3 cells with 
low passage MHV-68-D2-ORF65-GFP, higher passage MHV-68-D2-ORF65-mCherry or 
MHV-68-D2 as a control for 24 h and blotted the lysates. As depicted in Figure 3-15, a 
polyclonal MHV-68 specific serum was used as a virus-expression control. 
 
An antiserum against GFP revealed one band running shortly under 50 kDa. The same was 
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found with an antiserum reactive against mCherry (bands labeled with “a” inFigure 3-15. The 
monoclonal antibody 12B8 (43), reactive against MHV-68 SCP, detected bands running at the 
same height in lanes corresponding to GFP- or mCherry-tagged virus. As the ORF65-GFP 
and ORF65-mCherry fusion proteins had a theoretical molecular weight of 49 kDa, we 
assumed that these bands are the fusion proteins. Additionally, a band running between 25 
and 20 kDa could be detected in all lanes corresponding to virus infected cell lysates (bands 
labeled “b” in Figure 3-15 with the anti-SCP antibody. As WT MHV-68 SCP has a theoretical 
molecular weight of 22 kDa, this fitted nicely. Notably, the amount of WT MHV-68 SCP 
expressed by the tagged viruses seemed to be decreased in comparison to non-tagged MHV-
68. Moreover, the proportion of mCherry-tagged SCP to WT SCP seemed to be lower than in 
the case of GFP-tagged MHV-68, which might be because higher-passage virus stock was 
used to infect cells in the case of mCherry-labeled virus. 
 
 
 
Figure 3-15: Capsid-tagged MHV-68 mutants express only one ORF-65-FP isoform. 
Immunoblot of NIH-3T3 cells either mock-infected (1) or with a MOI of 1 of MHV-68-D2 (2), MHV-68-D2-
ORF65-GFP (3) or MHV-68-D2-ORF65-mCherry (4). Cells were infected at a MOI of 1 and harvested 24 hpi 
by lysis in total lysis buffer. Proteins were separated by SDS-PAGE, blotted and immunoprobed for GFP, 
mCherry, MHV-68 SCP. A polyclonal anti MHV-68 antiserum (101) as well as an antiserum against beta-actin 
served as loading controls. Lower case letters indicate specific protein bands. The detected banding pattern with 
the anti SCP antibody matches the pattern detected in immunoblots from purified virus particles. 
 
3.4.3 MHV-68 capsid-tagged viruses are not stable over extended passages 
 
As we observed a decrease in the ORF65-mCherry-specific signal when we used a higher-
passage MHV-68-D-ORF65-mCherry inoculum compared to a low-passage MHV-68-D-
ORF65-GFP inoculum MCMV (Figure 3-15), we reasoned that the MHV-68-D-ORF65-FP 
genomes might not be stable over extended passages. We therefore assessed the genetic 
stability of ORF65-GFP labeled virus compared to its parental MHV-68-D2 virus by 
reconstituting these viruses from their respective BACs and passaged them on NIH-3T3 cells 
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for up to 10 passages. We could follow the loss of fluorescence over extended passages. 
Moreover, we sequenced four PCR-products spanning the whole insertion site as well as 
adjacent genome areas after passages 0, 5 and 10. Interestingly, we could not detect any 
sequence alteration, but a decrease in PCR products which indicated a loss of the GFP fusion 
sequence most likely due to recombination with the WT locus (data not shown). This notion 
was further supported by the fact that a virus deleted in WT SCP but ectopically tagged with 
the SCP-GFP fusion regained its WT SCP cassette after extended passages (data not shown). 
Therefore, we purified MHV-68-D2-ORF65-GFP by limiting dilution. Virus stocks were 
prepared from these limiting dilutions by restricting passages to an absolute minimum. In 
general, no more than 3 passages after limiting dilution were allowed. All used virus 
preparations used, were checked for non-fluorescent revertants by plaque-assay and staining 
against MHV-68 with an antiserum (101). 
 
3.5 Normal morphogenesis of S-FP-SCP tagged recombinant MCMV 
 
To analyze whether virus morphogenesis is affected due to the expression of the S-GFP-SCP 
fusion protein, cells were infected with S-GFP-SCP virus and processed for transmission EM 
48 h post infection. As depicted in Figure 3-16, all major steps of virus morphogenesis e.g. 
capsid assembly, capsid packaging, primary envelopment in the nucleus as well as secondary 
envelopment appeared to be indistinguishable from WT virus with respect to phenotypic 
appearance and overall frequency. However, in some nuclei of S-GFP-SCP infected cells, 
semi-crystalline structures could be detected (data not shown). These structures mostly 
consisted of non-filled capsids similar to what was observed previously for a HSV VP26-
mRFP virus (22), but also during WT HSV infection (74). These data demonstrated that the 
major intracellular steps of the viral life cycle appeared to be normal in the fluorescent tagged 
MCMV recombinant virus. 
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Figure 3-16: Ultrastructural assessment of S-GFP-SCP infected cells. 
NIH-3T3 (upper row) or M2-10B4 cells (lower row) were infected at a MOI of 0.5 and centrifugal enhancement 
with WT (upper row) or S-GFP-SCP labeled virus (lower row) and incubated for 48 h. Afterwards, cells were 
high-pressure frozen, freeze-substituted, plastic-embedded and thin-sectioned. Depicted are representative details 
of two independent experiments showing non-enveloped B- and C-capsids in the nucleus (first column), primary 
envelopment in the nucleus (2nd column), non-enveloped C-capsids near cellular membranes possibly during 
secondary envelopment (third column), as well as enveloped capsids in the cytoplasm (right column). Scale bars 
indicate 200 nm. 
 
3.6 MCMV and MHV-68 fluorescent capsids are transmitted between cells 
 
Next, we analyzed whether fluorescent virus particles spread from cell to cell in tissue culture. 
To this end NIH-3T3 cells were seeded on cover slips in 24 well plates and infected with a 
low MOI of either MCMV S-GFP-SCP or MHV-68 ORF65-GFP (100 PFU per 50000 cells). 
To prevent virus spread via the supernatant, we overlaid the infected cells with carboxy-
methyl-cellulose as described for standard plaque assay (81). Four days after infection, the 
overlay medium was removed, plaques were fixed and IF was performed. MCMV MCP was 
detected by a specific polyclonal antiserum and compared to S-GFP-SCP fluorescence. MHV-
68 SCP was detected by a monoclonal antibody and compared to ORF65-GFP fluorescence. 
In addition, TO-PRO-3 (MCMV) or Hoechst33258 (MHV-68) was used to stain cell nuclei.  
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Figure 3-17: MCMV fluorescent virus particles are spread-competent. 
Confluent M2-10B4 cells were infected with S-GFP-SCP labeled virus on cover-slips in 24-wells with 100 PFU 
per well and overlaid with methyl-cellulose. 4 dpi cells were fixed and processed for immunofluorescence. 
MCP-specific antiserum was used to detect virus producing cells as well as single virus particles while GFP 
fluorescence was visualized directly. Cell nuclei were counterstained with TO-PRO-3. Inserts depict single virus 
particles surrounding a cell nucleus (circles) not showing any evidence for being on the late stage of infection 
and producing infectious particles. Scale bars indicate 20 µm in the upper row and 5 µm in the lower row. 
 
As shown in Figure 3-17 and Figure 3-18, cells at the center of a plaque exhibited abundant 
MCP stain and GFP fluorescence (yellow) inside nuclei, indicating a late infection stage. 
Cells at the edge of the plaque (Figure 3-17, insert 1 and Figure 3-18, insert 1), however, 
lacked any MCP or GFP signal in their nuclei, indicating that these cells did not started de 
novo synthesis of MCP, SCP or the GFP-SCP fusion proteins.  
Yet, in some of these cells, we could detect fluorescent spots next to the nucleus, adjacent to 
the nuclear rim (Figure 3-17 insert 2 and Figure 3-18, insert 2 as well as lower rows each). 
These spots were positive for both GFP fluorescence and MCP or SCP stains. Therefore, we 
concluded that these particles were virus particles that were transported to the nucleus of 
freshly infected cells. This finding suggested that labeled MCMV as well as MHV-68 virions 
were correctly transmitted from infected to non-infected cells. 
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Figure 3-18: MHV-68 fluorescent particles are spread-competent 
Confluent NIH-3T3 cells were infected with ORF65-GFP labeled virus in 8-well slides with 100 PFU per well 
and overlaid with methyl-cellulose. 4 dpi cells were fixed and processed for immunofluorescence. An SCP-
specific monoclonal antibody (43) was used to detect virus producing cells as well as single virus particles while 
GFP fluorescence was visualized directly. Cell nuclei were counterstained with Hoechst 33258. Insert1 depicts a 
single nucleus surrounded by various virus particles not showing any evidence for being on the late stage of 
infection and producing infectious particles. Insert 2 shows a magnification with virus particles surrounding and 
on top of the nucleus.  Scale bars indicate 50 µm in overview, 5 µm in the first magnified insert and 1 µm in the 
lower row. 
 
3.7 Labeled MHV-68 particles can be visualized throughout the infection cycle 
 
To follow the general morphogenesis of ORF-65-GFP tagged MHV-68 over time and control 
if the GFP fluorescence matches the capsid-incorporated SCP-distribution, we infected NIH-
3T3 cells in channels with MHV-68-D2-ORF65-GFP at a MOI of 10 and incubated the cells 
at 4° C. Afterwards we shifted the cells to 37° C and allowed entry. Thereby, we achieved a 
simultaneous infection. 
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Figure 3-19: ORF65-GFP can be detected throughout the infection cycle by its fluorescence 
NIH-3T3 in channels were infected at a MOI of 1 for one hour one ice, afterwards washed and shifted to 37° C. 
Cells were fixed 0, 0.5, 2, 6 and 24 hpi and stained with a monoclonal antibody specific for MHV-68 ORF65 and 
counterstained with Hoechst 33258. 0.5 hpi virus particles are translocated to the nucleus of cells. 6 hpi first 
signals of newly expressed ORF65 appear. Except for the cytoplasmic staining, the ORF65-GFP signal matches 
the anti -SCP signal. Scale bars indicate 5 µm. 
 
infection of the cells. Directly after shifting to 37°C or after 30 min, 2 h, 6 h or 24 h, we fixed 
the cells. As a control, we stained all samples with a monoclonal antibody directed against 
MHV-68 MCP and Hoechst 33258 to indicate nuclei. As depicted in Figure 3-19, 30 min after 
permitting entry, GFP-tagged virions could be visualized around the nuclei of cells. 6 hpi, 
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strong ORF65-GFP fluorescence could be detected, which even intensified 24 hpi. The 
ORF65-GFP pattern matched the anti-SCP staining except the diffuse cytoplasmic staining, 6 
and 24 hpi. 
3.8 Labeled MCMV capsids allow insights into beta-herpesvirus entry 
 
After verifying that the S-GFP-SCP recombinant had WT-like properties, we used this new 
virus to track MCMV-infection. To establish a particle tracking workflow, we aimed for a 
system with low background fluorescence and optimal imaging conditions. We therefore 
chose virus entry on cell protrusions, as virus particle movement is most easily observed in 
almost plane areas. To this end, M2-10B4 cells were seeded at low density and infected at 
high MOI (approx. 100 PFU/cell) with MCMV-S-GFP-SCP virus. For these experiments, all 
used virus stocks were gradient-purified and controlled by EM to verify the purity of viral 
particles. We then excited with 488 nm laser light and recorded simultaneously GFP emission 
as well as differential interference contrast (DIC) by confocal microscopy. By combining 
these two methods we could identify single virus particles with high confidence, as DIC 
allows, due to its high contrast, the visualization of very small objects floating in suspension 
while GFP fluorescence identified them as viral particles. 
 
We observed various attachment events at cell protrusions (data not shown) and could 
monitor movements of several virus particles. Figure 3-20 A shows 2 particles moving on 
such cell protrusion. To establish a quantification workflow, we used this phenomenon and 
tracked selected fluorescent signals that seemed to be attached to cell protrusions. For this 
task we used a custom written software package(51). It determines the position of a spot by 
fitting a two-dimensional Gaussian curve resulting in a very high, subpixel positional 
accuracy (45 ± 19 nm in this experiment). 
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Figure 3-20: Tracing of extracellular particle trafficking. 
M2-10B4 cells were seeded at low density on glass-bottomed culture dishes and infected at a MOI of 100 with 
gradient purified and EM-controlled S-GFP-SCP virus stock. Directly after infection, live imaging with 488 nm 
laser excitation as well as differential interference contrast (DIC) was started in an environmentally controlled 
chamber. Virus particles attached to cell protrusions were identified by their fluorescence and recorded with 1.8 
frames per second. (A) The changing positions of two fluorescent particles on a cell protrusion are depicted over 
time (circles). Numbers indicate individual particles. (B) Tracks of particle 1 and particle 2 (insert). No positions 
for the particles 1 and 2 could be obtained at time points when particle tracks overlapped, therefore each particle 
track is divided into two parts (both black for particle 1, red and black for particle 2. The 19 manually chosen 
subtracks in which particles clearly showed long distance movements are indicated by color overlays. The 
direction of movement is indicated by arrows. (C) Histogram displaying the distribution of measured mean track 
velocities for all used subtracks in which particles showed long-distance movements. (D) Histogram depicting 
the distribution of measured diffusion coefficients for the same subtracks as in (C). 
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Tracking of particle dynamics was done for the whole image sequence with the exception of 
the area in which particle tracks overlapped at some time points and particle identity was hard 
to define. Therefore, each particle track was divided into two parts (Figure 3-20 B). The 
resulting tracks were plotted and manually split into subtracks by choosing parts in which the 
particles clearly exhibited long distance movement (depicted as color-overlays in Figure 3-20 
B). Next, we determined the mode of motion for these subtracks. This was done by clustering 
them corresponding to their mode of diffusion. The mode of diffusion was determined by 
calculating the MSD and plotting them against the lag time. The resulting curves were then 
fitted according to three different diffusion models. These models were anomalous diffusion 
(MSD = 4Dtα), free diffusion (MSD = 4Dt) and directed motion with diffusion (MSD = 4Dt + 
(vt) 2). 
 
We divided the tracks of the two particles into 23 subtracks. Three of these subtracks showed 
free diffusion, one anomalous diffusion and 19 directed motion. From the latter we could 
determine the overall mean track velocity v. For the two selected particles the mean track 
velocity of all subtracks was 0.10 ± 0.05 µm/sec (Figure 3-20 C). Moreover, we determined 
the diffusion coefficient D from all subtracks. The mean of D was 5.87 ± 3.3 µm2/sec which 
indicated a high mobility (Figure 3-20 D). 
 
3.9 Quantification of cytoplasmic movement paths in herpesvirus egress 
 
Next, we wanted to know whether the quantification of intracellular particle movements 
during the late stages of infection is possible. For the following experiments, we used the 
mCherry-labeled MCMV variant named S-mCherry-SCP. Around 20 hpi, the first fluorescent 
signals emerged in nuclei of MEFs with detection parameters suitable for live-imaging (data 
not shown). Around 24 hpi, fluorescent spots of varying intensity could be followed in the 
cytoplasm. These spots most likely represented both, non-enveloped as well as enveloped 
viral particles, inside of vesicles. For alpha-herpesviruses, directed cytoplasmic transport of 
viral capsids is microtubule-dependent (61). We therefore asked if this is also true for the 
beta-herpesvirus MCMV. We infected MEF cells at a MOI of 0.5 with MCMV encoding the 
S-mCherry-SCP fusion protein and dissolved the microtubule network in control cells 23 hpi 
by the addition of 5 µg/ml Nocodazole for 1 h and subsequently imaged cytoplasmic 
fluorescent signals. An antibody stain against beta-Tubulin was used to control the effect of 
Nocodazole on infected cells (Figure 3-21). 
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Figure 3-21: Nocodazole treatment leaves no detectable Microtubule filaments after 1 h 
MEF cells were infected with MCMV-S-mCherry-SCP (red) at a MOI of 1. 23 hpi 5 µg/ml Nocodazole was 
added (Nocodazole) or not (mock) and cells were incubated further for 1 h. Afterwards, cells were fixed and 
stained for beta-Tubulin (white). Hoechst 33258 was used as nuclear counterstain. No intact Microtubule 
filaments are detectable after Nocodazole treatment. 
 
The disruption of the microtubule network had a dramatic effect on the motility of 
cytoplasmic fluorescent spots. As shown in Figure 3-22, cytoplasmic movements of 
fluorescent spots basically stopped, arguing for a microtubule dependent transport of the bulk 
of viral particles in the cytoplasm of MCMV infected cells. 
 
 
Figure 3-22: Nocodazole blocks MCMV fluorescent particle mobility. 
MEF cells were infected with S-mCherry-SCP for 23 h and treated with 5 µg/ml Noccodazole for 1 h or not. S-
mCherry-SCP-emission in live cells recorded under environmentally controlled conditions with 5 frames per 
second. Fluorescence intensity is coded in false-colors from dark blue to yellow. Three frames from a time-lapse 
stack each recorded 6 seconds (30 frames) apart are shown for a non-treated (upper row) and Nocodazole treated 
cell (lower row). Lines indicate the nucleus (Nuc.) as well as the cytoplasm (Cyt.). Circles indicate the position 
of a fluorescent particle. The right picture depicts all quantified tracks with ellipses marking the tracks from the 
particles highlighted on the left. 
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Figure 3-23: Quantification of particle tracks. 
(A) 180 particles from mock treated cells were tracked and their MSDs plotted against the lag time. Particle 
tracks were clustered into two classes representing mobile (left diagram) and immobile particles (right diagram) 
depending on the MSD trend. (B) 163 tracks from Nocodazole treated cells were clustered the same way as in 
(A). Mobile particles were further clustered depending on which mode of diffusion they exhibited according to 
their fit to three different diffusion models. (C) Distribution of particle mobility classes for mock- as well as 
Nocodazole-treated cells depicted in percent. The data is categorized into four classes (immobile, anomalous 
diffusion, free diffusion, directed motion). (D) Histogram displaying the distribution of mean track velocities of 
all particles exhibiting directed motion. (E) The same data as in (D) summarized in a box plot with median (line) 
mean (square), 25th to 75th percentile (box) and whiskers (5th to 95th percentile). (F) Histogram showing the 
distribution of all measured diffusion coefficients. (G) Box plot of the same data shown in (F). 
To quantify these cytoplasmic effects, we recorded the periphery of seven infected mock and 
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seven Nocodazole treated cells at five frames per second and subsequently tracked randomly 
most identifiable fluorescent particles (altogether 180 particles in mock-treated cells / 163 
particles in Nocodazole-treated cells). We then calculated their MSD curves and clustered 
them into two classes. The first class included all mobile particles and the second all 
immobile particles. We discerned between these two classes by analyzing their MSD curves 
and taking the experimental positioning accuracy of the used tracking algorithm into account. 
We determined an experimental positioning error of around 30 nm per axis which translates 
into approximately 14.500 nm2 in our MSD plots. All curves that did not exceed this value 
were classified as immobile, because their change in position during acquisition was less than 
the experimental localization accuracy of 30 nm per axis. In contrast, all particles that 
exceeded this value were classified as mobile (Figure 3-23 A, B). According to this 
quantification, 88.4 % of particles in mock treated cells were mobile. In contrast, 84.6 % of 
particles in Nocodazole treated cells were immobile. Yet, 15.4 % of the particles in 
Nocodazole treated cells were still mobile after 1 h incubation with 5 µg/ml Nocodazole 
(Figure 3-23 C). 
 
To analyze the properties of the mobile populations further, we fitted the corresponding MSD 
curves in a two-step process according to the three diffusion models described above (for 
details see materials and methods). 
79.2 % of mobile particle tracks in mock treated cells could be fitted with the function MSD = 
4Dt +(vt)2 compared to 6.2 % in Nocodazole-treated cells, indicating that a small fraction of 
particles in Nocodazole-treated cells exhibited directed motion, hinting to a possibly 
Nocodazole-resistant transport mode. 
 
Interestingly, Nocodazole treatment did not strongly influence the amount of particles 
diffusing freely (fit with MSD = 4Dt) or in an anomalous fashion (fit with MSD = 4Dtα) 
(Figure 3-23 C). Together with the strong increase of immobile particles under Nocodazole 
treatment, these findings might suggest that viral particles were either trapped in a very small 
molecular cage or fixed to some molecular anchor after Nocodazole treatment. 
 
As we fitted the mobile fraction of particles that exhibited directed movement with  
MSD = 4Dt +(vt)2, we could directly determine the overall mean velocity of a given particle 
track without its diffusion component. As shown in Figure 3-23 D, mean track velocities 
(over the complete acquisition time of approximately 20 sec) in mock treated cells had a mean 
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of 0.101 ± 0.073 µm/sec. In Nocodazole treated cells, however, particles that exhibited 
directed movement had a mean track velocity of only 0.041 ± 0.042 µm/sec. This finding 
indicated that high mean track velocities are based on a Nocodazole-sensitive (microtubule-
associated) transport mode. 
 
The second parameter we could determine was the diffusion coefficient D. It was calculated 
for all mobile particles and the median in mock-treated cells was 1.24·10-8 cm2/s while 
0.56·10-8 cm2/s in Nocodazole-treated cells (Figure 3-23 E). Interestingly, the distribution 
width of D in mock treated cells was higher than expected for a monodispersed particle 
suspension (Figure 3-23 E). D is inversely proportional to the hydrodynamic radius of a 
particle, as long as all other variables like temperature and the viscosity of the medium are not 
changed (D = kT/6πηr). Therefore, the observed distribution of D could be an indicator for a 
wider range of tracked particle diameters and different particle types e.g. non-enveloped 
capsids and enveloped capsids or enveloped multi-capsid assemblies. 
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4 Discussion 
 
This thesis describes the construction, characterization and first application of beta- and 
gamma-herpesviruses that are genetically tagged at their capsid by FPs for live cell imaging. 
Only the fluorescent tagging of the viral capsid allows the tracking of all steps of HV 
morphogenesis by fluorescence microscopy, as it is the first specific viral morphological 
structure made out of proteins. In contrast, approaches that utilize a tegument protein (91) or 
an auxiliary capsid protein added later after initial capsid assembly (15, 16) might not be able 
to study all steps of HV morphogenesis. That is why we decided to fluorescently tag a core 
capsid protein like the SCP. But in contrast to alpha-herpesvirus, all capsid proteins, including 
the SCP, are essential in the beta- and gamma-herpesvirus subfamilies. Therefore, a labeling 
strategy had to be found that either did no affect the biological properties of the target proteins 
at all or inevitable labeling effects had to be compensated to allow the generation of viable 
mutants. 
 
The general herpesvirus capsid structure is a highly ordered and evolutionary optimized 
assembly with numerous protein-protein-interactions. Thus, almost every mutagenesis 
approach will almost certainly interfere with its function to some extent. Therefore, as applied 
in the case of HSV-1 (24) we also chose the SCP as a fusion partner. This small protein is 
positioned at the outermost of the capsid structure (Figure 4-1.) This should give maximal 
sterical freedom to insert a bulky fluorescent protein. Nevertheless, previous studies reported 
no success with exchanging the WT SCP with a simple FP-SCP fusion in beta-herpesviruses 
(8, 88). Moreover, even the widely used HSV-1 and PRV SCP-FP mutants were reported to 
be biologically impaired (52, 72) and only viable because the SCP is not essential for viral 
growth in these viruses. This non-essentiality of the alpha-HV SCP might be due to a different 
structure of the capsid hexon (Figure 4-1) (104). We therefore concluded that it might be very 
difficult to generate an FP-capsid fusion protein that is close to indistinguishable from the WT 
parent in all its multiple functions. Yet, herpesvirus capsids consist of multiples of each 
capsid protein with 900 copies in the case of the SCP. The phenomenon that a wt allele can 
compensate for a non-functional mutation present on a separate allele is well known in 
herpesvirus genetics. It was utilized to map temperature-sensitive mutants in the past (93) 
Therefore, we speculated that placing the tagged allele in addition to the WT allele into the 
virus genome, can result in a functional capsid. 
We therefore split our approach into two steps: The first step was to engineer a FP-SCP fusion 
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that was not inhibitory and was as comparable to WT as possible. The second step was then to 
express this recombinant fusion protein from a second locus in addition to the WT SCP. In 
the resulting virus, the WT SCP fraction should complement for possible deficiencies of the 
FP-SCP fusion protein (cross-complementation). 
 
To find a concept for engineering optimal FP-SCP fusions, we employed multiple sequence 
alignments of a wide array of related herpesviruses. We could define conserved protein 
regions and linker sequences in between. Such linker sequences were subsequently used to 
insert the FPs. In the case of MCMV, the FP was inserted by duplicating the conserved N-
terminus and adding additional linker sequences. In the case of MHV-68, the FP was inserted 
directly into the C-terminus. 
 
 
 
Figure 4-1: Comparison of hexon morphologies for KSHV, SCMV and HSV-1 
Structures oft he E-hexon (hexon on the icosahedral twofold axis) determined by cryoelectron microscopy 
viewed from the top and from the side. The hexon structure in KSHV-and SCMV (gamma-and beta-HV) are 
similar, while the HSV-1 structure (alpha-HV) is different with respect to the outer chimney-like protrusions at 
the top of the hexons which most likely are SCP densities. (Figure adapted from (104)). 
 
To express the FP-SCP fusion proteins in addition to the WT SCP, the coding sequences were 
inserted ectopically into the viral genomes. To this end we used the pO6-vector system (10) 
that allowed us to insert the expression cassettes in a quick and versatile way by Flp-mediated 
recombination. The FP-SCP fusion sequences were first inserted into these plasmids and put 
under the control of their own promoters to maintain physiological levels of expression. As all 
elements needed were encoded on the plasmid, simple restriction enzyme-based cloning could 
be used to modify the cassette. This allowed us to change FPs and whole expression cassettes 
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very quickly and adopt them to technical needs. 
 
In a second step, the resulting plasmids could be transferred into the virus BACs by Flp-
mediated recombination. Under these conditions, the WT locus was not touched and the 
mutant SCP was expressed ectopically in cis. This system has a big advantage compared to 
classical homologues recombination (89) typically used to modify large herpesvirus genomes. 
First, a high percentage of resulting clones was positive for the inserted vector. Moreover, the 
danger of recombinase-based reshuffling of the repetitive sequences present especially in the 
MHV-68 genome was strongly reduced by the use of the Flp-recombinase which catalyzes 
selectively the recombination between specific FRT sites. 
 
However, this approach has also disadvantages. An ectopic insertion site is needed with a 
different genomic context that might lead to differences in the expression levels. Moreover, 
the tolerance for genome oversize varies from virus to virus. Thus compensating deletions 
elsewhere in the virus genome might be necessary. Also, as discussed in details later, 
recombination between the WT and ectopic loci can be a problem. 
 
Altogether, this strategy resulted in the assembly of capsids that carried a mixture of 
approximately one third of labeled and two thirds of unlabeled SCP in the case of the 
MCMV-S-GFP-SCP mutant, and approximately two fifth of labeled and three fifth of non-
labeled SCP in the case of the MHV-68-D2-ORF65-GFP mutant. 
 
Proving our premise, the remaining non-labeled SCPs were important, as recombinant 
MCMV and MHV-68 BACs in which the endogenous SCP locus was deleted could not be 
reconstituted (data not shown). Interestingly the recombinant MCMV carrying S-HA-SCP 
was viable after a functional deletion of the native SCP locus (data not shown) arguing for 
tag-size dependent inhibitory effects. One explanation are sterical constraints as the bulky 
fluorescent protein might be perhaps too large to fit six times into a volume which can be 
occupied by one hexon, while a mixture of unlabeled and labeled SCPs does. Another 
explanation is that the labeled variant cannot engage in essential interactions with neighboring 
proteins. As not all molecules are needed to engage in this interaction, the unlabeled 
proportion of SCP molecules is needed to compensate this deficit.  
 
The S-GFP-SCP fusion protein was incorporated into virus particles. This is most likely due 
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to its interaction with MCP. However, we cannot exclude that the S-FP-SCP as well as the 
MHV-68 SCP-GFP fusion proteins lack binding functions other than to MCP that have to be 
substituted by endogenous SCP. Therefore, although our mutant fusion proteins are not a 
substitute for WT SCP, they are not inhibitory as shown either by virus growth kinetics, 
plaque diameter and genome to PFU ratios. The WT-virus like properties of the new 
recombinant FP tagged viruses represented an important success. As in the case of MCMV 
the N-terminal GFP-SCP fusion constructed earlier in our laboratory showed a very strong 
dominant negative effect on virus growth (88). The difference between the MCMV GFP-SCP 
and S-GFP-SCP fusions is essentially the duplication of the first 34 aa that are added to the N-
terminus of the fluorescent protein. These 34 aa might apparently engage in important 
interactions or provide additional flexibility that discerns the S-GFP-SCP fusion from its 
dominant negative ancestor gfp-SCP.  
 
Further examination of the S-GFP-SCP recombinant virus showed that this virus was 
genetically stable for at least ten passages, supporting the notion that the S-GFP-SCP fusion 
did not inhibit virus growth as attenuating features often favor compensatory sequence 
alterations. 
In the case of MHV-68 expressing SCP-GFP we noticed slightly reduced growth kinetics 
compared to the MHV-68-D2 parent but not compared to WT MHV-68. During passaging we 
found the occurrence of non-fluorescent plaques which reoccurred after purifying fluorescent 
virus by the limiting dilution. Sequencing of the ectopic locus gave evidence for the loss of 
GFP tagged SCP over time. Most likely this is due to recombination of the large homologues 
ORF65 promoter and coding sequences flanking the inserted FP with the WT-locus of another 
MHV-68 genome during replication. This would lead to one genome having two copies of 
tagged SCP while the other would have two WT SCP copies. As WT SCP is needed for 
replication, the double-labeled genome would not grow, while the other would. This 
hypothesis was underlined by a MHV-68 SCP-knockout mutant with an additional SCP-GFP 
in the ectopic locus. Here, the WT ORF65 locus as well as the promoter region could not be 
removed completely due to overlapping ORFs. This mutant almost did not grew at the 
beginning but then reverted to normal growth. As it showed fluorescence it was not a WT 
contamination. Sequencing as well as immunoblotting confirmed the reestablishment of the 
WT locus in this passaged mutant (data not shown). Therefore, recombination between the 
remaining ORF65 sequences and the ectopic locus must have occurred. Hence it seems as if 
recombination between the ectopic locus and the WT locus regularly occured in MHV-68 but 
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not in MCMV. Herpesviruses are known for their strong recombinogenic potential, a fact that 
was used for decades to generate mutants before the advent of BAC technology. Therefore, in 
future studies the ectopic MHV-68 SCP-FP site should contain a synthetic, codon altered, 
SCP coding sequence. This way, recombination and loss of the fluorescent virus should 
become less frequent. 
Moreover, it is possible, that MHV-68 has a lower tolerance for genome oversize than 
MCMV. As only the M1 gene (1598 bp) is deleted in the parental MHV-68-D2 genome, 
insertion of the pOTO-ORF65-FP vectors lead to an approximate genome oversize of 1653 
bp. This might reduce the viability of genomes carrying the ORF65-FP cassettes and favor the 
replication of genomes carrying adoptive mutations. 
 
When we checked for phenotypic changes in the ultrastructure of MCMV S-GFP-SCP 
infected cells, we could not find obvious morphological differences except for some cells that 
showed parachrystalline arrays in a late stage of infection which seemed to be B-capsids. 
Notably, this phenomenon is also described for HSV-1 carrying an mRFP-tagged SCP as well 
as for WT HSV-1 infection (22, 74). 
 
The quantification MCMV and MHV-68 capsid labeling intensity as well as the proportion of 
labeled particles revealed that most particles are labeled to an extent that permitted particle 
tracking. Interestingly, labeled MHV-68 particles appeared to be much brighter than MCMV 
S-GFP-SCP particles. Moreover, immunoblotting indicated a possible decrease in the 
expression of WT-SCP compared to FP-labeled SCP. Also, only one major form of FP-
labeled MHV-68 could be found while labeled MCMV expressed different isoforms that were 
incorporated into virions. Taken together, these factors argue for a superiority of the MHV-68 
mutant in some applications, where brightness is an issue. However, genetic stability of the 
MHV-68 mutants remains an issue. 
 
Altogether the results of the characterization of our MCMV as well as MHV-68 mutants 
stressed the importance of a thorough quantification of the generated mutants. In the case of 
HSV- and PRV capsid labeled mutants this was initially not carried out (24, 99). Later studies 
(52, 72) revealed that labeling of the SCP in these viruses had the same effect on the growth 
kinetics as the deletion of the respective gene. As it is not completely known which additional 
functions the SCP has in alpha-herpesviruses, an ectopic labeling strategy might be preferable 
also in these viruses to compensate possible functional artifacts due to the lack of the WT 
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protein. Moreover, other capsid proteins like the MCP might be considered as alternative 
fusion partners. However, due to its size and different conformational structures in pentons or 
hexons, an appropriate insertion site is hard to predict. A random insertion approach could be 
a solution. The random mutagenesis approach published earlier by this group might be a basis 
(10, 58). 
 
To test if our new recombinant viruses could be used for SPT, we tested purified virus 
preparations of MCMV S-GFP-SCP in an assay for cell entry and detected particle attachment 
to cell protrusions and trafficking along those. We were able to establish a tracking workflow 
with few particles that resulted in a very accurate localization of single virus particles (45 ± 
19 nm) with high temporal resolution over extended time frames. Compared to recently 
published data for retroviruses (56) and also HSV-1 (26, 75) where also FP-labeled viruses 
were used, our data was acquired with 1.8 frames/sec., which is 17 to 53 times faster than in 
the studies mentioned above. These two factors together gave us the possibility to track 
particle movements with much higher accuracy. Moreover, by fitting the resulting MSD 
curves we could determine the overall mean track velocity separately from the diffusion 
coefficient D. Thereby, we found that the tracked particles showed iterations of directed 
movement, likely due to an active transport mechanism as recently described for retroviruses 
(56) and also HSV-1 (26, 75). In contrast to data described there, we were able to resolve the 
iteration of periods of directed motion and obstructed diffusion by manual track segmentation 
as well as its associated fluctuations in velocities with much higher spatial precision and 
temporal resolution. We found a mean track velocity of 0.10 ± 0.06 µm/sec for the measured 
tracks which is three to four fold higher than reported in other other studies (0.025 µm/sec - 
0.033 µm/sec (56, 75). Yet, the small number of experiments only shows the feasibility of the 
approach. To pin down the exact transport mechanism in the future, more extensive studies 
are needed with a considerably larger sampling to thoroughly quantify extracellular transport 
of MCMV as it was recently done for chemically labeled papillomavirus (94). 
 
Tracking extracellular viral particles provides a favorable environment with low background 
and low particle densities. Particle movement in the cytoplasm during virus egress, however, 
happens in an environment characterized by high background noise, high particle counts and a 
reduced cell cross section due to virus induced cell rounding. We tracked particles shortly 
after they first appeared in the cytoplasm and tracked their motility. As negative-control we 
used infected cells treated with the microtubule depolymerizing drug Nocodazole. By using a 
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fitting approach we could cluster the obtained particle tracks into four classes representing 
immobile particles and mobile particles exhibiting either anomalous diffusion, free diffusion 
or directed motion. We found that almost 80 % of particles showed a diffusive behavior 
indicative of directed transport. Nocodazole treatment reduced the fraction of mobile particles 
drastically. This effect was mainly due to the reduction of particles exhibiting directed motion 
(79 % to 6 %), while the proportion of particles exhibiting free or anomalous diffusion did not 
change strongly. This was anticipated as it was shown before that viral cytoplasmic transport 
is mainly microtubule-mediated. However, it was surprising that the dissociation of 
microtubules by Nocodazole did not increase the proportion of free or anomalous diffusing 
particles (4.4% to 6.8% and 5.2 % to 2.5 % respectively). This finding might indicate that 
particles are still bound to microtubule fragments after Nocodazole treatment as the tracking 
data indicated a very large proportion of particles that did not move more than the localization 
precision of 30 nm (classified as immobile). Yet, other mechanisms for immobilization of 
capsids, such as entrapment in a molecular cage or fixation to a molecular anchor, are also 
possible. 
 
The second surprising finding was that still around 6 % of particle tracks from Nocodazole-
treated cells could be fitted according to a directed motion model. Two explanations seem 
plausible. First, the remaining movement upon treatment with Nocodazole may be caused by 
the presence of stabilized Nocodazole resistant microtubules, similar to those which have 
been described for HSV-1 infections (31). Alternatively, the observed Nocodazole-resistant 
movement is based on actin filaments, a hypothesis that is underlined by the recent report 
describing the dependence of HSV-1 virion secretion on Myosin V (84) as well as by a 
comparable study using a tagged tegument protein (60). However, to specifically address 
these questions, future experiments are needed. 
 
Notably, instead of a focused distribution of the diffusion coefficient as anticipated for a 
monodisperse solution of particles we found a wider distribution of D. Assuming a uniform 
cytoplasmic viscosity this finding would translate into a non-uniform distribution of vesicle 
sizes used by the virus to transport particles. As we could observe a great difference in vesicle 
sizes containing virus particles in transmission EM (Fig. 3-16 and data not shown) this 
interpretation fits to the observed phenotype. Moreover, it demonstrates the power of single-
particle tracking to probe the environmental conditions of the measured particles without the 
need of co-labeling. 
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We calculated mean track velocities from particle tracks which could be fitted according to a 
model for directed movement. Notably, these mean track velocities were much smaller than 
what is reported for HCMV (91). This might have several reasons apart from intrinsic 
differences between HCMV and MCMV: First, we randomly accepted all particles that were 
technically possible to track. We did not select for mobile particles. Therefore, our mean step 
velocities must be smaller as more slowly moving particles were included. In addition, we 
used a different tracking and calculation approach. The mean track velocities used here 
display the mean velocity a given particle exhibits over the whole measured track. As we did 
neither select for fast transport processes during tracking nor used track segmentation as in 
Figure 3-20, again our mean track velocities had to be smaller than velocities from selected 
(sub-) tracks. The approach taken here should therefore be closer to approximate a realistic 
mean transport velocity with which cytoplasmic herpes particles are transported over longer 
time spans. 
 
Up to now, we did not quantify the cytoplasmic motility of MHV-68 capsids. Future studies 
are aimed at it. Moreover, the combination of the herein described capsids-tagged mutants 
with additional glycoprotein-FP fusions will enable the discrimination between enveloped and 
non-enveloped particles and thus will add more accuracy to the quantification. By including a 
membrane-tag it will also be possible to correlate the obtained diffusion coefficients to 
different particles from e.g. capsids and enveloped capsids. Also, future studies might include 
the direction of transport to produce a more detailed picture of cytoplasmic transport 
processes during herpes egress. 
 
Having solved the capsid tagging problem, also tagged tegument proteins might be employed 
to generate viruses labeled at the capsid, the tegument and the envelope as it was done for 
HSV (22, 72, 103). Altogether, these mutants can be now used to analyze the functions of 
viral and cellular proteins in virus morphogenesis. Especially the combination with different 
deletions of viral proteins might be of great interest to analyze their role in capsid transport. 
 
Perhaps the MHV-68 SCP-FP mutants can be applied in in vivo studies, as the used MHV-68-
D2 is only deleted in the M1 gene. This gene is not essential for lytic replication nor latency 
establishment in B-lymphocytes until 40 dpi (pers. comm. A. Vidy). The MCMV S-GFP-SCP 
cassette, however, would have to be transferred to another backbone, as the MCMV-∆1-16 
3 Discussion 
 
 69
virus poorly replicates in vivo. The ectopic expression cassette can be easily transferred by 
Flp-mediated recombination, and suitable non-attenuated viruses with enough coding space 
and an FRT site are reported (11, 53, 90). Thus, in vivo imaging of MCMV seems possible. 
Moreover, due to the modular architecture of the expression cassette, viruses expressing 
specialized fluorescent proteins for two-photon-imaging like mPlum (97) can also be 
generated rapidly. 
 
Altogether, by solving the capsid labeling problem we were able to generate the first viable 
recombinant beta- and gamma-herpesviruses that produce fluorescently labeled capsids. In 
comparison to the widely used HSV-1 and PRV capsid-tagged mutants (52, 72) the here 
described MCMV recombinant did not show any growth defect in cell culture and exhibited 
biological features comparable to their parental WT virus. All tested recombinants produced 
fluorescent virus capsids with an intensity sufficient to track single particles over extended 
periods in live cell microscopy. This allowed us to establish protocols to study the dynamics 
of beta-herpesvirus entry on cell protrusions for the first time. In addition, protocols for the 
analysis of intracellular particle transport during MCMV egress, for the first time with 
subpixel-spatial- and high temporal- resolution in the herpesvirus field, enabled us to 
characterize the cytoplasmic transport of a beta-herpesvirus with high detail. 
 
In summary, the results described in this study will enable the comparative study of alpha-, 
beta- and gamma-virus capsid dynamics. Especially, conserved nuclear transport processes of 
HV capsids will be of great interest in future studies. 
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5 Primer Sequences 
 
Table 1 
Primer Sequencea,b 
MCMV-for ATCATCCGTTGCATCTCGTTG 
MCMV-rev CGCCATCTGTATCCGTCCAT 
M54-as [FAM]-AACGTACATCGCTCTCTGCTGGCCG-6-carboxytetramethylrhodamine 
[TAMRA] 
SCPPfor GTGTGATATCGTCGTGCTGCGCGAGTCATCC 
SCPPrev GTGTCTTAAGACTAGTGGCGTAGTCGGGCACGTCGTAGGGGTAGCTGCTG
CCGCCGCTTCCTCC 
SP-AflII-FP-BsrGI GTGACTCTTAAGGCCACCATGGTGAGCAAGGGCGAGGA 
ASP-AflII-FP-BsrGI CACAGTTGTACAGCTCGTCCATGCCGCCGGTGG 
SP-MCP-binding-negative ATCGTGCAGCTGGACCTTTAAGACACACATACAGAAAAATAAA 
ASP-MCP-binding-negative AGTCACGGGCCCACATGTGCGAGGCC 
attB1-S-GFP-SCP-attB2-SP GGGGACAAGTTTGTACAAAAAAGCAGGCTTACTAGCTCTCTCTACTTTA 
attB1-S-GFP-SCP-binding-
neg-No-Stop-attB2-ASP 
GGGGACCACTTTGTACAAGAAAGCTGGGTAAAGGTCCAGCTGGTAGGCG
AG 
Delta M1 for TCGGGGGAGTCCAGGGTTTTCCCTAAGTATTACTGTTGGGATATCGCGCC
CACCTTTATTGTAAGGG 
Delta M1 rev CATTCTGAGTGGCACGAGAATTATTTGCATGTGTGTGAGCAGCCTTCCGG
CTCGTATGTTGTGTGG 
ORF65for GTGACTAATATTGAGAAACAGTTTAACATATG 
ORF65rev CACAGTTGATCAGCGAGCTCCTACTTTTTCTTTCCATTTC 
EGFP65for GTGACTAGGCCTGTGGTACGGACTGGGCGTGAGCAAGGGCGAGGAGCTG 
EGFP65rev CACTGAAGGGCCCCCCTTGTACAGCTCGTCCATGCC 
mCherry65for GTGACTAGCGCTGTGGTACGGACTGGGCGTGAGCAAGGGCGAGGAGGA 
mCherry65rev CACAGTGGGCCCCCCTTGTACAGCTCGTCCATGC 
 
a Underlined nucleotides: cleavage sites for restriction enzymes 
b Italic nucleotides: protein tags 
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6 List of Abbreviations 
 
aa amino acid 
AlHV1 alcelaphine herpesvirus 1 
AP assembly protein 
BAC bacterial artificial chromosome 
BHK baby hamster kidney cells 
BSA bovine serum albumine 
CCD charged coupled device 
CLSM confocal laser scanning microscope 
CPE cytopathic effect 
DBPS Dulbecco´s phosphate-buffered saline 
DIC differential interference contrast 
dpi days post infection 
E early 
EBV Epstein-Barr virus 
EHV-1 equine herpesvirus 1 
EM electron microscopy 
FCS fluorescence correlation spectroscopy 
FP fluorescent protein 
FRAP fluorescence after photobleaching 
GFP green fluorescent protein 
HA hemagglutinin 
HCMV human cytomegalovirus 
HHV-6 human herpesvirus 6 
HHV-7 human herpesvirus 7 
hpi hours post infection 
HSV-1 herpes simplex virus 1 
HSV-2 herpes simplex virus 2 
HV herpesvirus 
IE immediate early 
IF immuno fluorescence 
KSHV Kaposi-sarcoma associated virus 
L late 
MCMV murine cytomegalovirus 
MCP major capsid protein 
MEF murine embryonic fibroblasts 
MOI multiplicity of infection 
MSD mean square displacement 
NA numerical aperture 
ND10 nuclear domain 10 
NLS nuclear localization signal 
ORF open reading frame 
OvHV1 ovine herpesvirus 1 
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PCR polymerase chain reaction 
PFA paraformaldehyde 
PFU plaque forming units 
PORT portal protein 
POX peroxidase 
PR maturational protease 
PRV pseudorabies virus 
PTLD postransplant associated lymphoid disease 
SCP small capsid protein 
SDS sodium dodecyl-sulfate 
SPT single particle tracking 
TBS-T TRIS-buffered saline with Tween 
TRI1 triplex monomer 1 
TRI2 triplex monomer 2 
VZV varicella zoster virus 
Y2H yeast two hybrid 
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